

SUBJECT INDEX TO VOLUME 12

- Abacavir 1078
- ABC transporters 313
- ABCG2 (BCRP/MXR/ABCP) 314
- Acetylcholinesterase217,4378
 functions of 217
 in Alzheimer's disease 222
 in APP processing 4378
 in autoimmune disease 222
 in cancer 222
 in neurological disorders 222
 in organophosphate poisoning 222
 in β -amyloid deposition 4379
 non-classical functions of 220
 peripheral anionic site of 217
 role in rational drug design 217
 structure of 217
- Acetylcholinesterase inhibitors 4377
 targeting β -amyloid pathogenesis *via* 4377
- Activin A 881
 cellular signal transduction mechanism of 881
- Acyclovir 1348
 resistance to 1348
- Adapter proteins 4126
- Adaptive immunity 133
 role of dendritic cell- T cell interactions
 in initiation of 133
- Adenosine 3811
- Adherens junction 2817
 formation of 2817
- Adhesion molecules 2797,2837,2849
 as targets for anticancer therapy 2856
 as targets for treatment of neoplastic
 diseases 2849
 biological role of 2849
 chemoprevention in 2858
 in autoimmune diseases 2798
 in immune response 2797
 targeting for cancer therapeutics 2839
 therapeutic implications of 2855
 to deliver therapies 2842
 with co-stimulatory molecules 2808
- ADP 859
 effect of platelet ATP on receptors of 859
 platelet P2Y₁/P2Y₁₂ receptors for 859
- Agarose-gel electrophoresis 643
- Age-related neurodegenerative disease 699
 antioxidants in 699
 therapy against 699
- Aging 3147,3161
 animal models of 3166
 antagonistic pleiotropy theory of 3163
 cytokines in 3161
 gender differences in 3162
 neuro immune endocrine interaction in 3148
- role of hormones in 3148
 role of mitochondria in 3161
 role of systems biology in 3161
- AIDS vaccine 2017
 against autoimmune diseases 2024
 anti-idiotypic vaccines as 2018
 dendritic vaccines as 2022
 HIV virion-based 2022
 interferon alpha/cytokines as 2019
 peptide vaccines as 2018
 peripheral blood-derived inactivated
 vaccines as 2019
 peripheral blood-derived live vaccines as 2020
 plasmid-based vaccines as 2018
 poxvirus-based vaccines as 2018
 recombinant envelope vaccines as 2017
 retrovirus-based vaccine as 2018
 therapeutic type of 2017
 virus-like particle/VLP vaccine as 2018
- ALK-1 1180
 in haploinsufficiency 1182
 role of 1181
 structure of 1180
- Allergic asthma 3293
 nucleic-acid based technologies for 3293
 treatment by targeting transcription factors ... 3293
- Allergic diseases 3298,3930
 IgE in 3930
 pathophysiology of 3298
 role of transcription factors of TH2 cells in .. 3298
- Allergy 2350
 as TH2-mediated disorder 2350
 molecular target for therapy of 2355
 role of regulatory T cells in 2352
 T cell control in 2356
 treatment of 2358
- Allograft rejection 2384
- Alopecia areata 3794
- Alpha 7 nicotinic acetylcholine receptors 677
 effect on amyloid accumulation 677
 pathological/therapeutic significance of 682
 role in Alzheimer's disease pyramidal
 neurons 677
- Alpha adrenergic blockers 3812
- Alzheimer's disease (AD) 661,677,685,691,699,705,719,
 4283,4295,4313,4389,2559,4357,2569,4337
 amyloid beta toxicity in 699,4315
 amyloid hypothesis for 699, 4283,4295
 amyloid α -secretase activators for 4298
 amyloid γ -secretase inhibitors for 4305
 anthocyanins in 712
 anti-amyloidogenic for 4359
 antioxidant therapy of 701
 antioxidants in 699
 apoE in 723
 apoptosis in 4395
 approaches to immunotherapy for 4288
 astrocytes accumulate A β 42 in 681

Aβ42 accumulates intracellular in	678	role of β-amyloid fibrils (fAβ) in	4357
Aβ42 in	681	secretase inhibitors for treating	4295
APP as source of Aβ in	4306,4314	γ-secretase as pharmacological target	
beta amyloid in	4393	in	4317,4400
biochemistry of	705	selective modulation of Aβ42 production in ..	4337
brain inflammation in	719	β-sheets breaker peptides for	2561
cell cycle in	691	testosterone in	692
cholesterol in	719,723	therapeutic strategies for	687,4393
clinical diagnosis of	4313	therapy against	699,4297
clinical hallmarks in	4389	vaccine development for	4283
clinical trials of Aβ vaccination for	4287	vascular changes due to aging in	681
COX-2 inhibitors for	4399	vitamin C in	708
cytokine cycle in	722	vitamin E in	709
decrease amyloid β production for	4298	Amidoximes	80
demographics of	4295	as prodrugs of amidines	80
dense-core amyloid plaques in	678	Amino acid sequence	4091
epidemiology of	691,705	Aminoglycosidic antibiotics	3652
estrogen in	692	mechanism of action of	3652
etiology of	4295	AMPA receptor	3584
fibril-destabilizing effects in	4359	pharmacology of	3585
flavanols in	711,712	Anaesthetic drugs	3665
gamma-secretase in	4313	binding sites on ion channels	3666
genetics of	4295,4313	clinical effects of	3665
glia-derived oxidative burst in	706	diversity of molecular/clinical actions of	3669
glutamate in	719,727	effect on GABA _A receptors	3666
gonadotropins in	694	in knock out/knock in mice	3671
hormonal fluxes in	691	linking molecular/clinical actions of	3671
hydroxystilbenes in	713	Meyer-Overton correlation of	3665
hypothalamic-pituitary-gonadal axis in	693	molecular actions of	3665
immunization paradigms for	4284	Anesthetic	1931
immunopathology of	720	G protein-coupled receptors as target of	1935
in cerebellum	681	5-hydroxytryptamine (5-HT serotonin)	
inflammation in	706,723	receptors as target of	1933
inflammatory processes mediating		metabotropic glutamate receptors as	
complement autotoxicity in	722	target of	1935
lipoic acid in	710	muscarinic receptors as target of	1932
mechanism of neurodegeneration in	706	orphan receptors as target of	1935
mechanisms of clearance in	4286	substance P receptors as target of	1933
microglia activation in	728	Angiogenesis	1512,2380,2398,2599,2609
mitogenic abnormalities in	691	2631,3101,4458	
molecular/biochemical features in	4389	as therapeutic target in arthritis	2631
α7nAChR in	681	chemokines in	3102
neurofibrillary tangles in	4392	cytokines in	3107
neuropathological hallmarks in	705,4313,4390	direct inhibition of	2636
neuroprotective therapies for	705,708	genes related to	1512
NMDA antagonists in	713	indirect inhibition of	2638
non-peptidic γ-secretase inhibitors for	666	inhibition of	2634
non-peptidomimetic amyloid β-secretase		processes of	2632
inhibitors for	4302	VEGF receptor signaling in	2610
non-steroidal anti-inflammatory drugs in	4337	Angiogenesis imaging	2667
overstimulation of glutamate receptors in	707	after chemotherapy/radiation therapy	2668
oxidative stress in	681,700,4393	during/after anti-angiogenic therapy	2668
pathology of	677	role of	2667
peptidic γ-secretase inhibitors for	663	Angiogenesis inhibitors	2623
peptidomimetic amyloid β-secretase		combination of radiotherapy plus	2627
inhibitors for	4299	combination treatment strategies of	2627
pharmacological target in	4313	endothelial growth factor interfering	
polyphenols in	710	agents as	2624
presenilins in	4315,4391	in surgery	2628
prevalence of	677	role in medical/surgical/radiation oncology ..	2623
preventives/therapeutics for	4297,4357		
reactive oxygen species in	706		
role for gonadotropins in	685		
role of cell cycle in	4398		
role of c-Jun N-terminal kinase			
pathway in	4397		

- Angiogenic growth factors 557
 clinical trials using 557
- Angiotensin-converting enzyme (ACE) 2057
- Angiotensin converting enzyme inhibitor 517,2057
 anti-inflammatory effect of 2061
 biological plausibility of 2060
 clinical studies of 2058
 effect on neurotransmission 2061
 effect on skeletal muscle 2057
 effects on angiogenesis 2061
 experimental findings in animal models 517
 genetic studies of 2059
 human studies of 520
 implications for older adults 2062
 in arrhythmias 518
 in coronary circulation 520
 in myocardial infarction 520
 in ventricular function 518
 mechanisms of myocardial protection by 520
 metabolic effect of 2062
 muscle fiber type effect of 2061
 nutritional effect of 2061
 to protect heart in cardiac surgery 517
- Anisotropic polarizable molecular mechanics 2121
 applications of 2121
 development of 2121
 fluctuating charge models for 2123
 induced dipoles in 2122
 to study interactions involving flexible
 molecules 2132
 to study ligand/drug-receptor interactions 2121
 validation of 2121
- Annelids 3043
 cellular immune responses in 3043
 humoral immune responses in 3044
 immunity in 3049
- Anti-AIDS drugs 1341
 inhibition of reverse transcriptase by 1341
 mechanisms of drug resistance of 1341
 mechanisms of resistance to 1342
- Antiangiogenic agents 2624
 in clinical trials 2624
- Anti-apoptotic molecules 2911
 in ischemia/reperfusion injury of liver 2911
- Antiarthritic agents 2437
 novel targets for 2437
- Anti-cancer agents 363
 antibodies as 363
 differentiation antigens as 364
 TAA-binding antibodies as 365
- Anti HCV drug 1340,1375
 inhibition of NS5B activity by 1340
 mechanism of drug resistance of 1340
 non-nucleoside inhibitors as 1340
 nucleoside inhibitors as 1340
- Antibody drugs 2007
- Antigonadotropins 685
 lack of estrogen in 686
 novel strategy for Alzheimer's disease 685
- Antihistamines 2501
 desloratadine as 2505
 ebastine as 2504
 fexofenadine as 2504
 mechanisms of 2505
 stimulating effects of 2501
 terfenadine as 2503
- Anti-HIV therapy 1949,2031
 broad-spectrum pre-clinical inhibitors for 2045
 combination entry inhibitors for 2045
 coreceptor-based inhibitors for 2042
 CXCR4-targeted inhibitors for 2044
 ENV/CD4-based inhibitors for 2041
 FDA-approved antiviral drugs for 2032
 non-nucleoside reverse transcriptase
 inhibitors (NNRTI'S) for 2034
 preclinical/clinical drugs for 2037
 principles of combination therapy in 2036
 ribonucleotide reductase (RRI) inhibitors for 2039
 treatment interruptions (TIs) in 2036
 use of cytokines as immunomodulators in 2039
 viral targets for 1949
- Anti-HSV drugs 1360
 cellular targets for 1360
- Anti-hypertensive drug therapy 1557
 compliance with 1559
 in hypertensive patients 1557
 symptom perception in 1559
- Anti-inflammatory drugs 2437,2825
 in treatment of neurodegeneration 3512
 leukocyte adhesion target for 2825
 non-selective compounds as 2828
 novel targets for 2437
 selectin inhibitors as 2827
 targeting LFA-1 by 2826
 targeting TNF α /TNF α -induced
 pathways by 2827
- Antimicrobial drugs 4054
 for antituberculosis therapy 4054
 under development 4055
- Anti-neoplastic agents 113
 monoclonal anti-bodies as 113
- Antioxidants 3527
 effects of 3527
 for AD/PD/ALS 3527
- Antioxidant vitamins 599
 in lung cancer 599
 role in body 600
- Anti-picornavirus therapies 1379
- Antiplatelet agents 1287
 in management of intracardiac closure
 devices 1287
- Antiplatelet drugs 1293
 primary/secondary stroke prevention with 1293
- Antiplatelet peptides 887
- Antiplatelet therapy 1271
 lipophilic statins in 1272

Antiretroviral agents	1065,1075,1091,1129	Antiviral therapy	1339
adverse events of	1075	targeting viral polymerase	1339
attachment inhibitors as	1098	Apoptosis	328,4396,4412,4433,4455
characteristics of ideal type	1067	β A induces	4396
co-receptor binding antagonists as	1099	BCL-2 family proteins in	328
cost of	1071	in tumor cells	4445
development of	1065	reactivation as strategy to sensitize tumors	4417
drug interactions of	1071	redox modulation of signaling pathways	
entry inhibitors as	1070,1098	regulating	4433
fusion inhibitors as	1101	regulation of	328,4445
implications in therapeutic drug monitoring ..	1129	role of nitric oxide in	4445
in pediatric population	1138	signaling pathways of	4412
integrase inhibitors as	1101	Apoptotic signal transduction	4469
limitations of	1065	Aromatic anticonvulsants	3373
maturation inhibitors as	1101	immunologic cross-reactivity of	3375
non-nucleoside reverse transcriptase		lymphocyte transformation tests for	3376
inhibitors (NNRTIs) as	1094	patch tests for	3376
non-nucleoside reverse transcriptase		toxic cross-reactivity of	3376
inhibitors as	1068	Arsenic trioxide	117
nucleoside reverse transcriptase inhibitors		Arthritis	3551
(nRTIs) as	1091	antioxidant defenses in	3560
of malabsorption/toxicity	1138	chemotaxis/phagocytic cells in	3557
pharmacokinetics/pharmaceutics of	1070,1129	collagen in	3559
protease inhibitors (PIs) as	1069,1095	effects of free radicals on target tissues in	3557
Antiretroviral therapy	1015	free radical generation in	3551
effect on immunity	1015	hyaluronic acid in	3559
in patients infected with HIV	1015	production of hydrogen peroxide (H ₂ O ₂) in	3557
Antisense oligonucleotide BCL-2	121	production of nitric oxide (NO) in	3553
Antithrombotic drugs	73,1287,2425	production of peroxynitrite (ONOO ⁻) in	3555
heparin as	2429	reactive oxygen species in	3551
metabolism-directed optimization of	73	role of nitric oxide in	3551
oral anticoagulants as	2428	synovial fluid in	3558
pharmacogenetics of	2425	Artificial sweeteners	4596
platelet GPIIb-IIIa receptor/antagonists as	77	hT1R3's TMD binding site for	4596
platelet inhibitors as	2425	Aspirin	3347
prodrug strategies of	73,78	Aspirin resistance	251
prophylaxis by	1287	clinical significance of	251
thrombolytics as	2429	extrinsic mechanisms of	252
Antituberculosis drugs	4047	in coronary heart disease	255
rifabutin/rifapentine as	4051	in heart failure	256
rifalazil as	4053	in peripheral arterial disease	256
Antituberculous agents	4047	in stroke	255
development of	4047	intrinsic mechanisms of	253
<i>in vitro/in vivo</i> antimicrobial activities of	4047	mechanisms of	251
rifabutin/rifapentine as	4051	prevalence/clinical significance of	255
rifalazil as	4053	Asthma	2365,3195,3221,3233,3241,3261,3281
Anti-VEGF therapy	391	airway remodeling in	3234
Antiviral agents	1328,1371	aspirin induced	3199
for HBV/HCV-associated liver diseases	1373	cytokines in	2365
SF1 helicase inhibitors as	1328	biopharmaceutical therapeutics for	
SF2 helicase inhibitors as	1329	remodeling in	3233
SF3 helicase inhibitors as	1332	candidate gene strategies for	3195
targets of	1372	clinical efficacy of ICS/LABA	
Anti-viral drugs	1358	combination therapy in	3261
CDKS as targets of	1360	combination therapy with inhaled	
development of human/humanized		corticosteroids/long-acting β 2-agonists for	3261
monoclonal antibodies as	1397	corticosteroid design for treatment of	3241
in HSV-1 replication cycle	1358	cytokines in	3235
targets of	1358	epidemiology of	2365
		human asthma susceptibility genes in	2370

- immune stimulatory strategies for 3281
 immunopathogenesis of 2366
 immunotherapeutics of 2365
 inflammation in 3235
 mechanisms for efficacy of ICS/LABA
 combination therapy of 3269
 neovascularization in 3236
 NOS in 3222
 pathogenesis of 2365
 pharmacogenomics of 3195
 prevention by induction of TH1 responses 3281
 prevention/treatment of 3281
 role of CD4⁺ regulatory T cells in 3285
 structural insights of 3241
 subepithelial fibrosis in 3235
 toll-like receptors in 2365
 Atazanavir 1086
 Atherosclerosis 877
 activin in 879
 expression of TGF- β family in 877
 gene therapy for 877,881
 Atorvastatin 1549
 effect on diabetic retinopathy 1550
 in diabetic vascular complications 1549
 ATP 863
 platelet P2X₁ receptor for 863,868
 Atrial fibrillation 3639
 Kv1.5 in 3639
 Autoimmune disease 131,161,3699,3707,3735,3799
 agonist/antagonists LP receptors in 164
 analytical tools for 3735
 animal models for 3700,3707
 anti-adhesive strategies for 3802
 bioinformatics resources for studying 3709
 clinical trials of 3802
 comparative genomics for investigation of 3707
 dendritic cell-T cell synapse as
 determinant of 131
 gene expression in 3709
 genetic linkage analysis/association
 studies of 3708
 genetic variability in 3707
 immunological synapse in 135
 intergenomic comparison with exogenous
 factors 3714
 interpretation of global expression data of 3717
 modeling antigen presentation in 3715
 molecular pathways in 3712
 non-GPCR lysophospholipid receptors in 164
 pathogenesis 131
 proteomic approaches in 3699
 putative lysophospholipid GPCRs in 164
 QTG identification of 3712
 regulatory immunological synapse in 137
 therapeutic strategies by interfering
 with leukocyte endothelium interaction 3799
 Autoimmune pancreatitis 3781
 animal models for 3782
 clinical/pathological/laboratory findings in ... 3781
 epidemiology of 3781
 molecular pathogenesis of 3782
 treatment of 3782
 Autoimmunity 165,3743
 angiogenesis in 165
 expression studies of 3748
 promoter studies of 3744
 role of HLA promoters in 3743
 lysophospholipids in 165
 Avian cytokines 3083
 as adjuvants 3093
 Avian interferons 3089
 AZT resistance 1815
 role of insertions in mechanism of 1815
 A β fibrillogenesis 4358
 assay system for 4358
 A β 42-Lowering compounds 4344
 clinical trials with 4349
 development of 4349
 mechanism of action of 4344
 Bacterial infections 4185
 interaction between TLR4/TLR2 in 4188
 TLR polymorphisms as risk modulators in ... 4185
 TLR2/TLR4 expression during 4185
 Bare metal stents 1282
 BCL-2 antisense 329
 clinical studies with 329
 Benign prostatic hyperplasia 775
 alpha-1-adrenergic antagonists in 779
 dutasteride trials for 781
 finasteride vs. terazosin in 779,780
 inhibitors of 5 α -reductase in treatment of 755
 medical therapy of prostate symptoms
 (MTOPS) trial for 780
 prostate cancer prevention trial for 781
 Beta lactams 3327
 diagnosis of allergy with 3331
 immediate hypersensitivity reactions to 3327
 immunological response to 3329
 Bioinformatics 2111
 open-source java library for 2111
 Biomaterials 2737
 Biomolecular networks 3723
 algorithms for 3729
 database/information resources for 3724
 deriving functional modules for 3728
 in mammals 3723
 integrating microarray data for 3727
 ontologies for 3726
 protein function annotation for 3726
 resources/tools for 3723
 Bioreductive drugs 4482
 BK_{Ca} channels 465
 Block copolymer micelles 4685
 formulation of drugs in 4685
 in drug loading/release 4685

Bone marrow toxicity	1018	Cancer	2398,2849,4411,4427,4479,4729
effect of antiretroviral drug-drug interactions	1018	alterations in apoptotic machinery in	4411
Bone morphogenetic protein (BMP)	877	antioxidant defense network in	4430
cellular signal transduction mechanism of	878	apoptosis loss in	4413
inhibition of signaling by cellular factors	879	cadherin-catenin complex in	2856
Bone regeneration	2401	CEA in	2857
Bronchial asthma	3175	cysteine redox transformations in	4430
airway hyperresponsiveness in	3176	diagnostic nuclear medicine techniques for ...	4731
allergic reactions in	3176	disturbed redox balance in	4480
animal models of	3175,3185	families of cell adhesion receptors in	2851
guinea pig	3181	genomic instability in	4413
in cat	3185	hematopoiesis/stem cells in	2399
in dog	3185	integrins in	2856
in ferret	3185	neural regeneration/engineering in	2399
in horse	3186	oncogenesis of	4413
in monkey	3184	photodynamic therapy in	4491
in pig	3186	polysulfide agents in	4487
in rabbit	3182	pro-oxidants/redox catalysts in	4489
in rat	3179	radionuclides for	4732
in sheep	3183	reactive oxygen/nitrogen species in	4428
inflammation in	3176	redox regulation of thiol dependent	
remodeling in	3178	signaling pathways in	4427
Calcium channel antagonists	3811	sensitivity of	4411
Calpain inhibition	615	sensor/effector drug design for	4479
as therapeutic strategy targeting multiple		treatment of	2398,4411
disease states	615	water-soluble polymers for	4739
Calpain inhibitors	627,4396	Cancer cells	287
neuroprotective effects of	4396	inhibition of multidrug resistance of	287
non-peptide inhibitors of	631	Cancer therapy	261,387
peptidyl aldehydes as	628	effect of tumor suppressor gene	
peptidyl epoxides as	628	inactivation on	266
peptidyl α ketoamides as	631	emergence vs. pre-existence of resistance to ...	264
Calpastatin	618	evolution of resistance to	261
in apoptosis	623	probability of resistance to	262
in atherosclerosis	626	VEGF inhibitors in	387
in cataract formation	627	Cancer vaccines	351
in cell migration	622	TRICOM vector based	351
in cell proliferation	623	<i>Candida albicans</i>	4263
in diabetes	626	human monocyte-derived dendritic cells by ..	4263
in ischemia reperfusion injury	625	<i>in vitro</i> infection by	4263
in muscular dystrophy	627	therapeutic implications of	4263
in neurological disorders	624	Cannabinergic drug targets	1754
in signal transduction	623	biological roles of	1754
in spinal cord injury	626	Cannabinergic system	1752
physiological substrates/function of	621	Cannabinoids	3135
platelet function of	622	effect on immune system	3135
regulation of activity of	618,620	Cannabinoid receptors	1751
structure of	618	as therapeutic targets	1751
Campath-1H	116	ligands for	1755
Camptothecin	315	Carbamates	80
as inhibitor of topoisomerase I	315	as prodrugs of amidines	80
Camptothecin analogues	313	Carcinogenesis	2379,4457
ATP-dependent transport in plasma		mechanisms of prostanoids in	2379
membrane vesicles of	321	nitric oxide in	4457
cellular accumulation of synthesized	320	Cardiac delayed rectifier K ⁺ channels	460
to circumvent ABCG2-associated drug		Cardiac hERG/I _{kr} potassium channel	2271
resistance of human tumor cells	313	as pharmacological target	2271
to circumvent drug resistance	318	clinical applications of	2271

- function of2271
 pharmacological modification of2278
 physiology/pathophysiology of2271
 regulation of2271
 structure of2271
 Cardiac voltage-gated potassium channelopathies ...3631
 molecular mechanisms of3631
 targeted pharmacological therapies3635
 Cardiac/pulmonary remodeling2689
 Cardiovascular diseases841,972,3945,4229
 α 2-antiplasmin in841
 arterial/venous thrombosis as842
 development of vaccines for4238
 effect of hemostasis843
 in elderly3945
 effect of inhibition of COX2 on972
 plasmin/plasminogen system in841
 prevention in elderly3951
 pulmonary embolism as843
 therapeutic targets in4229
 Cardiovascular risk1567
 abnormal glucose regulation as1567
 clinical studies of glycemic control in1572
 Cardiovascular system3490
 therapeutic options of PDE 5 in3490
 Carotenoids287,600
 MDR reversal effect on cell lines291
 role in body600
 Caseins1637
 Caspases4395
 in β -amyloid-induced apoptosis4395
 CBFA1878
 as transcription factor for BMP-induced
 osteoblast differentiation878
 CD2/LFA-32803
 based targeted therapeutic agents2803
 CD28149
 as positive costimulator of immune functions .150
 CEA-MUC-1/TRICOM360
 Cell therapy558
 clinical application of559
 in coronary artery disease559
 in peripheral artery disease559
 principle of558
 Cell type-specific signal proteins3015
 biology of3015
 cytoplasmic precursors of3017
 of protozoan ciliates3015
 physicochemical features of3017
 primary structures of3017
 sources/secretion of3016
 three-dimensional conformations of3017
 Cephalosporin3335
 allergenic determinants of3335
 cross-reactivity to3340
 immunological response to3329
 CFTR activators2242
 CFTR chloride channel activators471
 development of471
 discovery of471
 CFTR inhibitors2238
 Channel activating protease (CAP-1)2226
 Chemical genomics1717
 Chemically induced aneuploidy1489
 in mammalian germ cells1489
 mechanisms/risk of1489
 studies on identification/characterization of ..1494
 Chemistry development kit (CDK)2111
 3D model builder for2118
 with statistical software2114
 Chemokines3091,3101
 as regulators of angiogenesis3101
 avian C based3092
 avian CC based3091
 avian CXC based3091
 in health/disease3101
 Chemotherapeutic drugs329
 BCL-2 antisense mediated down-regulation
 of BCL-2 sensitizes myeloma cells to329
 Chemotherapy2837
 resistance to2837
 Chiral derivatizing agents (CDAs)4024
 Chiral lanthanide shift reagents (CLSRs)4033
 Chiral solvating agents (CSAs)4028
 Chondroitin sulfates640
 biological roles of640
 in pharmacological treatment of
 osteoarthritis641
 Chorea2702
 treatment of2702
 Chromatine119
 Chronic infectious diseases2329
 therapeutic modulation of cytokines in2329
 Chronic obstructive pulmonary disease
 (COPD)3207,3261
 clinical efficacy of ICS/LABA combination
 therapy in3267
 combination therapy with inhaled
 corticosteroids/long-acting β 2-agonists for .3261
 mechanisms for efficacy of ICS/LABA
 combination therapy of3269
 Cilostazol565
 against focal cerebral ischemic damage565
 chemistry of566
 pharmacology in brain ischemia566
 Cleft lip1431
 and 6-aminonicotinamide1433
 and amphetamines1435
 and hypoxia1433
 and maxillary hypoplasia in rats after

phenytoin dosing	1438	by diabetes mellitus	1613
and phenytoin	1431	by hypertension	1612
and salicylates	1435	by impaired glucose metabolism	1613
exogenous risk factors of	1431	by lipid abnormalities	1614
genetic risks of	1432	by smoking	1612
in susceptible mouse strains	1435	effect of dietary factors on	1617
mouse strains with spontaneous	1433	effect of obesity on	1616
role of HERG channel inhibitors with	1435	effect of physical exercise on	1616
role of hypoxia in mouse strains with	1435	in Indo-Asians	1611
teratogenic mechanisms of	1438	role of apolipoprotein A1/B in	1616
Clopidogrel	1261,1271	traditional risk factors for	1611
activated <i>via</i> CYP3A4/3A5	1271	traditional risk factors in Indo-Asians	1612
mechanisms of resistance of	1266	Coronary heart disease (CHD)	1612
metabolism of	1262	associated metabolic syndrome	1613
platelet inhibition by	1266	by diabetes mellitus	1613
resistance of	1261	by hypertension	1612
Coagulation enzymes	74	by impaired glucose metabolism	1613
Cognition	2487,2533	by lipid abnormalities	1614
biomarkers of	2533	by smoking	1612
cortical markers of	2533	effect of dietary factors on	1617
dopaminergic enhancement of	2487	effect of obesity on	1616
in experimental animals	2489	effect of physical exercise on	1616
Colloidal microgels	4703	epidemiology in UK Indo-Asians	1612
in drug delivery applications	4703	role of apolipoprotein A1/B in	1616
polymeric nanogels of	4704	traditional risk factors in Indo-Asians	1612
systemic drug delivery of	4704	Coronary stenting	1261
Colon cancer	2375	implications for	1261
cyclooxygenase involvement in	2376	Coronaviruses	1309,4573
epidemiological findings/clinical		inhibitor design for	4579
evidence of	2375	Corticosteroids	3241
role of prostaglandin receptors in	2376	airway activity of	3252
signaling pathways from activated		structural insights of	3241
prostanoid receptors in	2378	therapeutic potential of	3241
Colonic motor function	4077	Corticotropin-releasing factor (CRF)	4071
peripheral CRF receptors in stress-related		as mammalian family of peptides	4071
stimulation of	4077	binding proteins of	4073
Common mucosal immune system (CMIS)	4203	gastrointestinal distribution of	4072
Computational chemistry	1843	receptor antagonists of	4074
in development of anti-HIV drugs	1843	receptors for	4073
Computational protein design	3973	signaling pathways mediate acute stress	4075
applications of	3975	COX inhibitors	207
automatic design programs in	3991	Coxibs	971
major issues/problems in	3989	cardiovascular side-effects of	971
methods of	3987	chemical differences of	973
Connective tissue	639	pharmacological/clinical differences of	973
chondroitin sulfate analysis in	639	Coxsackieviruses	1384
physiological/pathological states of	639	animal studies of	1385
Contraceptive	3915	clinical studies for	1386
criteria for targets of	3919	experimental therapies for	1384,1387
hurdles for development of	3918	natural products for	1385
identification of	3915	cPGES	949
identification/validation of targets for	3921	expression/function of	949
Copper	2588	structure/enzymatic property of	949
in PrP ^c conformation/biosynthesis	2588	CrK family adaptors	530
Coreceptor switch	1113	CrK/CRKL SH3 binding proteins	532
Coronary atherosclerosis	1611	C3G as	532
associated metabolic syndrome	1613	c-Abl/Arg as	533
		DOCK proteins as	533
		P13 kinase as	533

- Cross talk2609
 between cardiovascular/nervous systems2609
- CTLA-4 149
 as therapeutic target 152
 expression/function of 150
 mechanisms of T cell inhibition by 151
- CTLA-4-Ig 149
 in animal models 153
 in clinical trials 155
 limitations in therapy by 155
 mechanisms of immunosuppression by 154
- Cutaneous autoimmune diseases 3787
 functional genome/proteome analysis of 3787
- CVD 1551
 effects of atorvastatin on 1551
 role of serum lipids in 1551
- CYC202 1954
 inhibition of CDK2/HIV replication by 1954
- Cyclic nucleotide-gated channels 3597
 effect of cyclic nucleotide derivatives on 3599
 hyperpolarization-activated type 3608
 pharmacology of 3597
 pore blockers/gating modifiers of 3602
 targeting in retinal disease 3607
- Cyclooxygenase-2 (COX-2) 205,3497,3847
 biology of 3498
 CRE/AP-1/NFAT/NF-16 regulation of
 transcription of 3503
 expression for anti-inflammatory drug
 development 3504
 expression of 3847
 imaging of 3847,3851
 in cancer 3849
 in disease 3847
 in inflammation 3848
 in neurological disorders 3850
 in vascular system 207
 inhibitors for 3851
 NF- κ B regulation of 3498
 PKC-dependent C-SRC regulation of 3498
 regulation by estradiol on endothelium 205
 transcriptional coactivators regulation of
 transcription of 3503
 use in diagnosis/drug evaluation 3847
- Cystic fibrosis 2235
 halide-sensitive fluorescent indicators in 2235
 inhibitors as antidiarrheals/activators for
 therapy of 2235
- Cystic fibrosis 471,4188
 activation of CFTR by NS004 in 476
 alkylxanthines in 474
 benzimidazolones in 476
 drug discovery assay for 474
 HTS technologies for 474
 milrinone in 476
 natural isoflavones in 476
 pharmacological agents for 474
 TLR2/TLR4 function in 4188
- Cystic fibrosis transmembrane conductance
 regulator (CFTR) 471,2235
- activation by benzoquinolizinium derivatives 478
 activation by phenanthroline/benzoquinolines 480
 allosteric activator of 480
 as ABC transporter with chloride
 selective pore 471
 drug discovery assay for 474
 HTS technologies for 474
 in chloride channel drug discovery 2235
 pharmacological agents for 474
 pharmacology of 472
- Cytokines 18,1392
 2330,2349,2397,2867,3025,3071,3101
 activities in vertebrates 3073
 as activators of professional phagocytes 2330
 as regulators of angiogenesis 3101
 as therapeutic target for allergic diseases 2349
 based therapy in parasitic infections 2339
 based therapy in viral infections 2337
 biological activity of 3071
 cannabinoids action on 3142
 in allergic inflammatory cascade 2349
 in cell mediated immunity 2331
 in chronic fatigue syndrome (CFS) 19
 in chronic infectious diseases 2331
 in fibromyalgia 19
 in health individuals 18
 in health/disease 3101
 in humoral immunity 2331
 in pharmacological modulation 2867
 like activities in invertebrates 3071
 mediated immune enhancement 1392
 network of 3135
 role in hepatic ischemia/reperfusion injury 2867
 signals during infection 2330
- Cytotoxic drugs 112
 mechanisms of drug resistance of 112
- DAPT 671
 effect on sprague dawley rat 671
 functional γ -secretase inhibitor 671
 oral administration of 671
 reduction of A β levels by 671
- Death signaling 4472
 by intracellular ROS 4472
- Dehydroepiandrosterone 3411
 as anti-proliferative 3411
 as chemopreventive agent 3411
 derivatives of 3411
 effect on tumors 3413
 endogenous metabolites of 3412
 mechanisms of anti-neoplastic action by 3414
- Dendritic cells (DC) 131,4247
 as modulators of effector/regulatory synapses 138
 identification of subsets of 4248
 pharmacological modulation of 141
 receptors for 4249
- Depressive disorders 507
 HPA system abnormalities in 507
- Deuterostomes 3008
- (1 \rightarrow 3)- β -D-glucan-binding of factors 4157

(1→3)-β-D-glucan-sensitive coagulation factors	4157	of tailor-made peptide	193
Diabetes mellitus	485,1567,2401	structure/function of	4574
Ca ²⁺ channels in	494	targeting protease in	4573
Cl ⁻ channels in	495	targeting T-cell adhesion molecules for	2797
clinical studies of glycemic control in	1572	therapeutic targets in	4583
glinides in	491	Drug development	1456,2532
K _{ATP} channels in	486	cognition disease targets for	2532
Na ⁺ channels in	494	process of	1456
pancreatic regeneration in	2401	Drug discovery	397,1301,1785,2087,2099,3963,3999
pathogenesis of cardiovascular events in	1567	as screening receptorome validated	
role of hypercoagulable state in	1567	molecular targets for	1785
role of hyperglycemia in	1567	aspartic protease in	1303
Diabetic nephropathy	1550,1551	automated electrophysiology in	401
effects of atorvastatin on	1550	biomolecular interaction analysis in	3999
effects of statins on	1551	3C protease as target in	1305
role of serum lipids in	1550,1551	cysteine protease in	1303
Diabetic retinopathy	1549	fluorescent dye assays in	400
advanced glycation end products (AGEs) in	1550	herpesvirus in	1310
role of serum lipids in	1549	immobilization strategies in	4009
Didanosine	1080	influenza virus in	1311
Diethylstilbestrol	1505	ion flux assays in	400
exposed neonatally	1505	ligand based virtual high throughput	
in carcinogenesis	1515	screening in	2099
Differentiation-inducing therapy	382	ligand binding assays in	399
as tumor dormancy therapy	382	metalloprotease in	1303
Dimerization	1900	NS2/3 protease in	1309
effects of NNRTIs on	1900	protein NMR-based screening in	3963
Dipeptide insertions	1818	serine protease in	1302
impact on viral fitness	1818	structural biology in	2087
Diterpenoids	287	togavirus in	1311
DNA virus-based vectors	1999	using surface plasmon resonance technology	3999
DNA/RNA polymerases	1868	Drug-encapsulated electrospun fibers	4755
nucleotide incorporation by	1868	Drug-herb interactions	4649
dNTP inhibition	1832	clinical outcomes of	4654
of primer-unblocking reaction <i>in vivo</i>	1832	mechanisms for	4650
Dopamine receptors	2487	strategy for eliminating toxicity	
as psychomotor stimulants	2492	arising from	4655
clinical implications of	2493	therapeutic drug monitoring of	4659
dopaminergic projections of	2487	Drug hypersensitivity	3309
in experimental animals	2489	drug-related risk factors for	3309
studies in humans	2490	epidemiology of	3309
DPP-IV inhibitors	1742	host-related risk factors for	3310
Drug delivery	4703,4713	β-lactam allergies/SNPs for	3311
hydrogels in	4713	risk factors for	3309
lipobeads in	4714	treatment regimen-related risk factors for	3310
liposomes in	4713	Drug loading	4686
mucoadhesive microgels in	4703	factors influencing	4688
nanocapsules in	4714	in block copolymer micelles	4686
nanogels in	4714	Drug molecular design	313
of macromolecular therapeutics	4709	transport mechanism-based	313
of small molecular therapeutics	4706	Drug release	4691
Drug design	191,2797,4573,4649	from block copolymer micelles	4691
affinity devices in	197	Drug screening	1703
antibody-like peptides for	191	G proteins in	1703
eliminating toxicity with	4649	Drug targets	538,1731
novel purification tool for	191	EGFR/ErbB/Her/Neu family of receptors in	538
		glucagon as	1731
		glucagon-like peptide receptors as	1731
		Dual TXRAs/TXSIIs	909

- Dutasteride 777
 pharmacology of 777
- 15-E₂₁-IsoP 899
 bioactivity of 899
- Echoviruses 1386
- Efavirenz 1082
- Electrically-assisted nucleic acids 3817
 delivery to tissues *in vivo* 3817
 electrode types in 3819
- Electrospinning 4751
 for tissue engineering applications 4763
 in nanomedicine 4751
 process of 4752
- Electrospray ionization mass (ESI-MS) 651
- Electrostatics 220
- Enantiodiscrimination 4023
 by NMR spectroscopy 4023
- Endocannabinoids 227,759,2319
 actions of 235
 as family of lipid mediators 2319
 effect on ion channels 227
 inhibition of neuritogenesis/synaptogenesis
 by 2322
 interactions with ligand-gated ion channels 230
 molecular targets of 759
 pathophysiological implications of 2323
 protection of neurons/glia by 2319
 receptor-independent effects of 227
 receptor-independent effects on voltage-gated
 channels 228
 regulation of neural cell development by 2319
 stimulation of neural progenitor cell
 proliferation by 2320
 metabolism of 761
- Endocrine 3147
 immune interaction with 3147
- Endoglin 1174
 functional studies on mutants of 1176
 structure of 1174
- Endothelin antagonists 3812
- Endotoxemia 4529
 gastrointestinal function in 4529
- Endotoxin 4229
- Enhanced permeability/retention (EPR) 4785
 cellular mechanism of 4788
 effect /significance of 4785
 effect in PDCs delivery 4793
 factors affecting 4786
 for tumor targeting 4785
 in polymer drug conjugate delivery 4785
 physiological requirement of 4786
- Enteroviruses 1383,1387
 experimental therapies for 1383
 polioviruses as 1383
- Epibatidine 3893
 radiolabeled analogs of 3893
- Epilepsy 2190
 antiepileptics in 2190
 role of T-type Ca²⁺ channels in 2190
- Erectile dysfunction 3467
 causes of 3471
 classification of 3471
 epidemiology of 3468
 organic causes of 3471
 pathophysiology of 3468
 peripheral causes of 3474
 phosphodiesterase 5 inhibitors in
 treatment of 3467
- Erythropoietin (EPO) 2693
- Estrogen 208,1505
 effects of 208
 effects on prostacyclin/COX 209
 mechanisms of action of 209
 receptors expression of 1506
- Eukaryote cells 2999
 formation of 2999
 origin of life of 2999
- Euplotes pheromones 3021
 structural relationships of 3021
 with other proteins 3021
- Extracellular matrix (ECM) 2923
 composition in liver 2923
- Extracellular signal-regulated kinases 1/2 (ERK1/2) 1683
 organization of generic elements of
 signaling of 1684
 physiological/cellular roles of 1683
 RAF/MEK-independent activation of 1695
 7TMR regulation of 1684
- Extracellular space 3820
 modulation of 3820
- Eye diseases 2645
 anecortave acetate for 2651
 antineovascular agents in 2645
 cyclooxygenase inhibitors for 2650
 inhibitors of integrins for 2652
 inhibitors of matrix metalloproteinases
 (MMPS) for 2653
 protein kinase C-β inhibitors for 2649
 renin-angiotensin system targeting drugs for 2649
 role of pigment epithelium-derived factor
 (PEDF) 2648
 somatostatin for 2653
 steroids for 2651
 thalidomide for 2651
 treatment of 2645
 triamcinolone acetonide for 2651
 use of endogenous inhibitors of
 angiogenesis in 2648
 vascular endothelial growth factor (VEGF)
 targeting drugs for 2646
 vascular targeting agents for 2654
- 15-F₂₁-IsoP 897
 bioactivity of 897
 renal effects of 897
- Factor G 4158
 activation of 4158

Factor Xa inhibitors	86	methodological framework for	60
Family C GPRCs	2159	multidisciplinary approaches for	59
<i>in silico</i> approaches for	2159	muscle relaxants in	13
ligand based approaches for	2167	nicotinamide adenine dehydrogenase	
ligand based/structure based approaches for	2169	(NADH) in	50
ligand binding domain of	2162	non-pharmaceutical treatments for	14
structure-function relationships in	2159	NSAIDs in	13
Fatty acid amide hydrolase	759	nutritional/herbal/hormonal	
as target for next generation therapeutics	759	supplementation in	48
natural inhibitors of	764	opioids in	13
synthetic inhibitors of	764	opthophysiology of	17
Female fertility	3915	physical therapy modalities in	29
hormonal contraceptives in	3916	S-adenosylmethionine in	50
intrauterine device (IUD) in	3917	serum dehydroepiandrosterone sulphate	
regulation of	3915	(DHEAS) in	50
Fetal alcohol syndrome (FAS)	1521	Siberian Ginseng in	48
mechanisms of	1526	ST.John's Wort in	48
pharmacology of	1523	superficial cold/heat therapy in	53
Fetal hypoxia syndrome	1440	transcutaneous electrical nerve stimulation	
Fetal phenytoin syndrome	1440	(TENS) in	30
Fibrinolytic agents	849	treatment of	12
development of	849	ultrasound in	30
first generation of	849	valeria in	49
second generation of	851	Fibromyalgia syndrome	3,23,37,67
Fibrin-specific thrombolytic agents	849	advances in imaging pain perception in	69
Bat-PA as	853	antidepressant drug in	3
staphylokinase as	853	assessment in patient subgroups in	69
Fibromyalgia	11,17,29,47,59	assessment of fatigue in	68
acupuncture/electro acupuncture in	30	assessment of pain in	67
antidepressants in	12	citalopram in	6
ayurvedic in	53	cognitive-behavioral treatment in	37,41
botanical oil in	49	core outcome domains in	69
chiropractic care in	53	depression in	4
<i>Chlorella pyrenoidosa</i> in	50	drug therapy in	4
cognitive behavioral therapy (CBT) for	14	duloxetine in	6
combination therapy in	11	evaluation of	67
complementary/alternative medical		exercise in	37
therapies in	47	fluoxetine in	6
conceptual framework for multidisciplinary		mechanisms involved in	3
approach to	60	milnacipran in	7
corticosteroids in	13	monoamine oxidase inhibitors in	5
cytokine based therapies in	17	muscle injections for local pain in	25
dietary supplement in	51	role of botulinum toxin injections in	26
drug development for	17	role of muscles for	24
electromagnetic field/magnetotherapy for	33	role of nociception for	24
electromyographic biofeedback training for	33	role of pain receptors for	24
electrotherapy for	30	role of peripheral sensitization for	24
etiology of	11	role of primary/secondary hyperalgesia for	24
exercise programs for	14	role of tender point injections in	23
growth hormone in	50	role of tonic nociception in	23
homeopathy in	53	selective serotonin reuptake inhibitors in	5
hormone replacement therapy (HRT) for	13	serotonin/norepinephrine RE uptake inhibitors in	6
5-hydroxytryptophan combination therapy for	51	tender points in	25
interventions in	54	therapeutic efficacy in	67
laser therapy for	31	trigger points of	25
magnesium in	49	venlafaxine in	6
management of	29,59	Finasteride	777
manual/manipulative technique in	52	pharmacology of	777
massage in	52	First-generation MDR modulator	277
melatonin in	49	Fish cytokine	3051
		biology of	3051
		in adaptive immunity	3051
		Flaviviridae	1307

- Flavonoids4271
 effect on acute/chronic inflammatory responses4271
 immunomodulating effects of4271
 regulation of receptor-mediated signal transduction by4276
 suppression of chronic inflammatory responses by4275
 suppression of *in vitro* TNF- α production by4271
 suppression of *in vivo* production of4274
- Flavopiridol1952
 anti-HIV effects of1952
- Fluorophore-assisted carbohydrate electrophoresis (FACE) analysis649
- Fluoroquinolones4048
- Foscarnet1348
 resistance to1348
- FP-TZTP metabolites3908
 identification of3908
- Frailty3147
 bone loss in3154
 components of3151
 definition of3149
 immunological correlates of3149
 of older age3147
 pathophysiology of3149
 prevalence of3150
 sarcopenia in3152
- FTY7204630
 clinical aspects of4630
- Fungal pathogens4198
 as pathogen recognition systems as escape mechanisms4198
- Fusion inhibitors1086
 enfuvirtide as1086
- G protein1703
 analysis of1703
 chimeric/promiscuous type1705
 family of heterotrimeric type1703
 in assay schemes for drug discovery1705
 specificity to manipulation of GPCR-mediated signaling pathways1703
- G protein-activated inwardly rectifying K⁺ (GIRK Kir3) channels4513
 as therapeutic targets4513
 distribution of4513
 pathophysiological/clinical implications of ...4517
 pharmacological modulation of4514
 physiological regulation of4514
 structure of4513
- G-protein coupled receptors1695,1704,1719, 1771,1797,2175
 analyzing receptor-G protein specificity with G α chimeras for1704
 and signaling promiscuity1720
 assay enablement downstream of G α subunits1720
- assay sensitivity to constitutive activity of1722
 complexity of1805
 computational strategies to2177
 coordinated covalent modification of1797
 for lysophosphatidic acid (LPA)162
 for sphingosine 1-phosphate (SIP)162
 information management/integration of1779
 ligand-based homology modeling for2175
 links to protein tyrosine phosphatases1695
 mutagenesis of1776
 palmitoylation of1798
 pattern recognition examples of1774
 phosphorylation of1797
 regulation of1720
 role for information collection/management/integration of1771
 sequence information of1772
 structural plasticity of2175
 structure-function studies of1771
 ubiquitination of1801
 universal assay for1719
- GABA_A receptors3668
 diversity of molecular/clinical actions of3669
 mediated synaptic transmission3668
- Gadolinium*3651
 mechanism of action of3651
- Gancyclovir1348
 resistance to1348
- Gastric lesions2978
 effect of sensory nerves on healing of acute/sub-acute type2978
- Gastric ulcers2977
 healing of2977
 role of sensory neurons in restitution of2977
- Gene therapy453,552,2969
 as calcium antagonism453
 for chronic granulomatous disease (CGD)552
 in liver ischemia/reperfusion injury2969
 in X-SCID patients552
 production of recombinant AD vectors for2970
- Germ cell aneuploidy1490
 methodologies for evaluation of risk factors for1490
- Glioblastoma344
 antisense strategies in344
 anti-TGF- β strategies in346
 decorin in344
 experimental approaches targeting TGF- β in ..344
 inhibition of TGF- β processing in345
 inhibition of TGF- β signaling in345
- Glucagon-like peptides1735
 therapeutic potential of1736,1741
- Glucagon receptor1731
 desensitization of1742
 family of1731
 in treatment of diabetes1733
 therapeutic potential of targeting1733
- Glucocorticoids (GCs)2828,3383
 cross-reactivity among topical/systemic3386

Glycine	2953	Hematopoietic malignancies	111
clinical safety of	2963	chemoresistance in	111
dosage/toxic side effects of	2963	chemosensitivity in	111
in animal liver transplantation	2961	molecular targets for	111
in human liver transplantation	2963	Hemopoietic colony stimulating factors (HCSFs)	2689
mechanism of action of	2954	in acute coronary syndromes	2691
mechanism of anti inflammatory action of ...	2956	in angiogenesis	2691
receptors for	2954	in arterial hypertension	2690
studies on cultured hepatocytes/sinusoidal		in atherosclerosis/vascular remodeling	2690
endothelial cells	2959	in cardiac remodeling/chronic heart failure ...	2692
studies on isolated perfused liver	2960	in cardiovascular/pulmonary remodeling	2689
therapeutic modulation of hepatic IRI by	2959	in myocardial ischemia	2691
Glycoprotein II b/III a receptor blockade	3812	Hepatic ischemia/reperfusion injury	2867
GM-CSF	2694	adhesion molecules in	2869
in idiopathic pulmonary fibrosis (IPF)	2694	anti inflammatory mediators in	2869
in lung fibrosis	2695	chemokines in	2869
modulating in lung	2694	interleukin-10 in	2870
Gonadotropins	687	interleukin-12 in	2867
cell cycle hypothesis of	687	interleukin-13/interleukin-4 in	2870
Gq protein-coupled receptors	1931	interleukin-6 in	2869
as targets for anesthetics	1931	proinflammatory mediators in	2867
Grb2 family adaptors	535	secretory leukocyte protease inhibitor in	2870
GRAP as	536	tumor necrosis factor alpha in	2868
Grb3-3 as	536	Hepatic ischemia-reperfusion injury	2875,2953
p27Kip1 as	536	generation of ROS in	2878
Sos as	535	H ₂ O ₂ in	2877
Grb2-coupled receptors	538	inhibition of O ₂ ⁻ generating systems for	2833
in human diseases	538	oxidative stress in	2875
Growth factors	1512,2397,3092	protective strategies for	2880
clinical applications of	2398	redox-active iron in	2884
mechanism of action of	2400	role of antioxidants in	2875
Gut	4526	role of glycine in	2953
innervation of	4526	ROS-formation in	2878
		ROS-mediated signals during	2879
		sources of ROS generation during	2879
		superoxide formation in	2878
H1-antagonists	2501	Hepatitis B	1139,1344
desloratadine as	2505	use of TDM in patients with	1139
ebastine as	2504	Hepatitis C virus	1339
fexofenadine as	2504	function of	1339
mechanisms of	2505	structure of	1339
stimulating effects of	2501	Hepatitis viruses	1371
terfenadine as	2503	adefovir dipivoxil (ADV) in	1374
H3-antagonism	2507	antiviral drug discovery for	1371
HCV-associated liver diseases	1371	entecavir in	1374
adefovir dipivoxil (ADV) in	1374	lamivudine in	1373
entecavir in	1374	levovirin in	1374
lamivudine in	1373	non-nucleoside analogues for	1375
levovirin in	1374	nucleoside analogues for	1374
ribavirin in	1374	pathogenesis by	1371
treatment with antiviral agents in	1371	ribavirin in	1374
viramidine in	1374	treatment with antiviral agents in	1371
		viramidine in	1374
Helicases	1315	Hepatorenal syndrome	4637
function of	1322	α-adrenergic agonists for	4639
structure of	1322	in liver cirrhosis	4637
virus control by	1315	pathophysiology of	4638
Hematopoietic cell	557,3033	pharmacological treatment of	4639
formation in leech wound healing	3033	vasoconstrictor therapy for	4637,4644
for therapeutic angiogenesis	557	vasopressin analogues for	4640

- Hepoxilin analogs 963
 anti-thrombotic actions of 964
 apoptotic actions in leukemia 965
 as therapeutics in disease 963
 in lung fibrosis *in vivo* 963
- Hereditary hemorrhagic telangiectasia (HHT) 1171,1173,
 1209,1237
 ALK1 in 1180
 and pulmonary arteriovenous malformations 1244
 as rare disease 1171
 cerebral arteriovenous malformations in 1245
 cerebrovascular arteriovenous
 malformations in 1227
 clinical aspects of 1217
 deficit of polymorphonuclear cell in 1209
 diagnostic imaging of visceral
 involvement in 1227
 endoglin in 1174
 endovascular treatment of pulmonary/
 cerebral malformations in 1243
 genetic/molecular aspects of 1173,1219
 genotype-phenotype correlation in 1188
 haplonisufficiency model for 1175
 hepatic arteriovenous malformations in 1231
 hormonal therapy for 1240
 immunological consequences in 1201
 in childhood 1221
 monocyte-derived tumor necrosis factor- α in 1201
 monocyte oxidative burst in 1209
 mutation screening of 1185
 pathophysiologic model for 1237
 phagocytosis in 1209
 pulmonary arteriovenous malformations in ... 1229
 screening for special patients 1221
 SMAD proteins in 1185
 T-helper 1 cell derived cytokines in 1201
 therapeutical approaches for 1229
 transforming growth factor β in
 pathogenesis of 1195
 treatment of recurrent epistaxis in 1237
- hERG 3633
 long QT syndrome 3633
- Herpes simplex viruses 1346,1357
 in antiviral drug discovery 1357
- Herpes simplex virus type UL5/UL52/UL8
 helicase 1319
- High-performance capillary electrophoresis (HPCE) . 647
- High-performance liquid chromatography (HPLC) 643
- High throughput screening 1717
 R-SATTM in 1718
 signal transduction pathways to 1717
- High-throughput ion channel screening technologies 397
 in integrated drug discovery 397
 integrated drug discovery using 403
- Histone deacetylase inhibitors (HDAC-inhibitors) 119
- HIV 1017,1125,1341,1943,1950,1963
 and role of P-TEFb 1951
 anti-infectives against 1017
 antiretroviral regimens not recommended for 1053
 antiretroviral therapy for 1046,1963
 antiretroviral-associated immunosuppress-
 ion in 1016
 associated dementia 1023
 attachment of 1964
 AZT against 1019
 based neuropathogenesis 1023
 CDKs in cellular transcription in 1950
 cellular entry of 1963
 cyclosporine in 1125
 effect on astrocytes 1026
 effect on endothelial cells 1026
 effects of flavopiridol/CYC202 on
 replication of 1951
 efficacy of HAART in 1016
 entry inhibitors against 1965
 entry of 1964
 env protein of 1964
 fusion inhibitors against 1049
 fusion of 1964
 hydroxyurea in 1122
 immune response in 1015
 immunosuppression against 1017
 implications for therapy of 1033
in vitro analysis of excess iron on
 infection in 1944
 iron chelation in 1945
 loss of neurons by 1025
 non-nucleoside reverse transcriptase (RT)
 inhibitors against 1048
 non-nucleoside-based regimens for 1050
 nucleoside reverse transcriptase (RT)
 inhibitors against 1046
 pathophysiology of 1024,1045
 postexposure prophylaxis for 1057
 protease inhibitor-based regimens for .. 1048,1050
 related neurological disease to 1024
 role of activated macrophages/microglia with 1024
 role of CDK2 in Tat transactivation of 1953
 therapeutic targets of 1963
 TMP/SMX against 1019
 treatment failure in 1053
 treatment guidelines for 1045,1049
 triple nucleoside-based regimens for 1053
 use of virostatics as target of 1121
 viral life cycle of 1950
 viral load testing of 1046
- HIV dementia 1026
 dopaminergic system in 1026
 Gp120 in 1031
 Gp41 in 1030
 host factors in 1032
 implications for therapy of 1033
 Nef in 1031
 Rev in 1032
 role of viral proteins in 1027
 Tat in 1027
 Vpr in 1031
- HIV reverse transcriptase (RT) 1909
- HIV RNase H 1909
 design of mechanism-based/selective
 inhibitors of 1914
 design of small molecule inhibitors of 1909
 effect of diketoacids on 1914
 effect of *N*-hydroxyimides on 1914

mechanism of RNA hydrolysis catalyzed by	1912
structure of	1909
HIV therapy	1975
chromatin modifications (acetylation/ deacetylation/methylation) as targets for	1975
chromatin/TAT-modifying enzymes as target of	1983
role of chromatin remodeling/ modifications in	1979
role of remodeling/covalent modifications in	1975
HIV vaccines	1147
CTL-based	1153
development of	1147
in human trials	1154
in human trials	1156
monomeric gp120-based	1150
SIV/macaque models of aids pathogenesis for	1152
structure relevant to design for	1147
trials of	1149
vector based	1156
HIV-1 entry	1106
via membrane fusion	1106
HIV-1 entry inhibitors	1105
CCR5-GP120 interface as target for	1110
CD4-GP120 interface as target for	1108
CXCR4-GP120 interface as target for	1112
in HIV-1 therapy	1105
interfere with receptor/coreceptor engagement by	1105
HIV-1 nonnucleosides	1858
FDA approved	1858
role in combination therapy	1859
HIV-1 protease	1303
as drug target/inhibitor of	1303
HIV-1 protease inhibitor	1303
agenase as	1305
fortovase as	1303
invirase as	1303
kaletra as	1305
lexiva as	1305
reyataz as	1305
viracept as	1305
HIV-1 replication cycle	1981
early phase of	1981
late phase of	1981
regulation of expression of	1981
HIV-1 reverse transcriptase	1811,1827,1872,1899
acceptor substrates for excision <i>in vivo</i>	1831
as antiviral target	1879
as therapeutics target	1885
dimerization of	1879
drug resistance to	1811
effect of ATP/PP on	1831
effect of chain-terminating nucleotides on translocational equilibrium of	1872
effect of inhibition of ATP-mediated excision reaction	1818
effect of natural substrates/inhibitors on	1827
effect of viral fitness of deletions in β 3- β 4	1819
hairpin loop of	1819
effects on drug resistance	1819
function of	1879
heterodimer interface of	1881
in infected cell	1827
<i>in vitro</i> vs. <i>in vivo</i>	1830
inhibition of	1812
insertions/deletions in	1811
intracellular site at	1830
nucleotide-dependent excision activity of	1827
primer-unblocking activity of	1828
sites of replication of	1833
structure of	1341,1812,1879
targeting protein interfaces of	1886
target on	1899
viral fitness of	1811
with insertions in fingers subdomain	1813
HIV-integrase	1853
HIV-protease	1843
HIV-RH inhibitors	1916
binding sites of	1916
from nucleotides/dinucleotides	1917
hydrazones as	1917
mappicine analogs as	1919
quinones/naphthoquinones as	1916
tropolone derivatives as	1919
HLA	3743
in autoimmunity	3743
pharmaceutical intervention in	3750
Horseshoe crab hemolymph coagulation system	4155
Host cell determinants	2040
and HIV-1 entry	2040
HSV-1	1362
effects of (S)/(R)-Rosco against	1362
5-HT ₃ receptors	3615
antagonists of	3622
distribution of	3615
function of	3616
heteromeric/homomeric receptors based	3625
ligand binding site of	3617
pharmacology of	3619
therapeutic potential of	3626
Human cognition	2474,2525
cardiovascular markers for	2534
endocrine markers for	2535
functional magnetic resonance imaging for	2534
in drug research	2525
models for	2528
positron emission tomography for	2534
process-vs. product-approach in	2530
resource models of information processing for	2529
role of behaviourism/experimental psychology in	2526
role of cognitive psychology in	2526
role of serotonin in	2474
Human infertility	767
expression in	767
FAAH activity in	767

- Humoral immune responses 174
 autoreactive natural antibodies in 174
 natural antibodies in 174
 regulation of 174
- Huntington's disease2563,2701
 pharmacological management of2701
 treatment of psychiatric symptoms in2710
- Hyperglycemia 1568
 link with hypercoagulable state 1568
- Hypersensitivity3313,3347,3373,3383
 C5A in3350
 cellular allergen stimulation test CAST in3350
 clinical aspects of3348,3384
 cross-reactivity in cell-mediated/IgE-
 mediated3383
 cross-reactivity studies of3373
 diagnostic tests for3373,3385
 etiologic role of preservatives in3386
 flowcytometric allergen stimulation test
 (FAST) alias basophil activation test
 (BAT) for3351
 genetic factors in3321,3350
 histamine release in3350
 IGE determination of3350
 immunologic cross-reactivity of3375
in vitro diagnostic assays for3350
 lymphocyte transformation tests for3376
 mediators involved in3348
 patch tests for3376
 pathogenic mechanisms of3383
 role of chronic inflammation in3349
 to aromatic anticonvulsants3373
 to aspirin3347
 to glucocorticoids3383
 to NSAIDs3347
 toxic cross-reactivity of3376
- Hypersensitivity reactions3327,3359,3393,3401
 by anesthetics3406
 by antiallergic drugs3406
 by antibiotics3404
 by antivirals3405
 by carbonic anhydrase inhibitors3404
 by erythema multiforme3405
 by herbal remedies3394
 by metals3397
 by parasympathomimetics3402
 by preservatives3407
 by propolis3397
 by prostaglandin analogs3404
 by sympathomimetics3402
 by β -blockers3403
 clinical evaluation of3330
 clinical manifestations of3361
 diagnosis of3367
 pathogenic mechanisms of3394,3401
 pathophysiology of3363
 prophylaxis for3368
 risk factors for3362
 therapeutic alternatives to3331
 to complementary/alternative medicine
 products3393
 to iodinated contrast media3359
 to ophthalmic products3401
- Hypertension 1558,1567,1581,1593,1623
 altered angiogenesis in1587
 angiotensin converting enzyme inhibitors for1562
 angiotensin II receptor antagonists for1563
 as inflammatory process1623
 beta-blockers for1561
 calcium channel antagonists for1562
 cardiovascular risk reduction in1593
 changes in angiotensin-II1586
 changes in matrix metalloproteinases1586
 cognitive impairment/vascular dementia in1583
 diuretics for1560
 dyslipidemia in1593
 endothelial dysfunction in1628
 evaluation of quality of life in1559
 high blood pressure in1628
 inflammation as initiator of1627
 inflammatory markers for1623
 left ventricular dysfunction in1582
 left ventricular hypertrophy in1582
 lipid metabolism in1593
 management of1567
 molecular mechanisms of1584
 oxidative stress in1629
 role of angiotensin II in1627
 role of C-reactive protein (CRP) in1624
 role of endothelium in1584
 role of interleukin 6/interleukin-1 β in1624
 role of platelets in1585
 role of thrombogenesis in1585
 role of tumor necrosis factor alpha
 (TNF- α) in1626
 statin therapy for1593
 statins for1594
 symptoms in1558
 therapeutic trials for1629
 vascular markers for1627
- Hypothalamic pituitary adrenal (HPA) system506
 treatment strategies influencing506
- Hypoxia1431
 and phenytoin1431
- Hypoxia-inducible factor-1 (HIF-1)2673
 activators of2681
 effect of alkaloids2675
 effect of amino acid derivative on2675
 effect of carbohydrates/glycolysis
 products on2681
 effect of phenolic compounds on2677
 effect of prostaglandin E₂ (PGE₂) on2680
 effect of terpenes/steroids on2679
 natural product-derived small molecule
 activators of2673
 therapeutic applications of activators of2682
- I-123 RS IQNB3903
 clinical studies with3903
- IgE3929
 in allergic diseases3929
 mediated diseases3929
 mediated diseases management of3931
- IgE-mediated hypersensitivity3335
 administration of cephalosporins in

patients with	3342	properties of	242
<i>in vitro</i> cellular tests for	3339	to promote remyelination in animal models	243
serum specific IgE assays for	3338	Immunological synapse	139
to cephalosporins	3335	effect of interaction of activating/inhibitory	
IGG autoantibodies	175	receptor pairs on	139
impaired control of	175	Immunomodulators	1393
in IVIG-treated patients	175	Immunosuppression	2212,4772
IgG dimers	181	as pathogenetic factor for post-trans-	
biological functions of	184	plantation dyslipidemia	4772
cross reactivity of	184	by inhibition of Kv1.3	2212
cyclic vs. open-chain dimers as	183	Immunotherapy	2569,4135
distribution of affinities/concentration of	184	for Alzheimer's disease	2569
formation of	181	for conformational diseases	2569,2578
in multidonor-derived immunoglobulins	181	for prion's diseases	2575
<i>in vivo</i> generation of	188	Toll gates for	4135
indications of FAB-FAB interactions in	181	Immunotoxins	368
plasma pooling as source of	181	Impaired endothelial cell (EC)	1543
IK _{Ca} channels	464	Indinavir	1085
IL-17 family	3084	Inflammation	1628,2437,3161,3509,3545
Imaging	2661	and aging	3510
evolution of angiogenesis/implications for	2661	and excitotoxicity	3511
of tumor perfusion/microvascular		antiinflammatory agents	2440
permeability	2662	arterial stiffness in	1628
Imatinib mesylate	118	chemical mediators involved in	2437
Immune cell manipulations	1395	energy metabolism in	3163
Immune complexes	173	gender differences in	3162
autoantibody-induced formation of	173	in neurodegenerative diseases	3511
in normal human serum	173	induced neurodegeneration	3509
Immune receptors	4091	NO scavengers in	3545
model study of	4091	role of mitochondria in	3161
<i>in silico</i> investigation of	4091	role of systems biology in	3161
Immune response	3822	Influenza virus	1349
Immune system	3135	Innate immune response	4123
cannabinoid receptors in	3135	Innate immunity	4203
CB1 receptor in	3136	in mucosal immune system	4203
CB2 receptor in	3136	Integrative functional assays	1717
effect of natural/synthetic/endogenous		Integrin	2723,2750
cannabinoids on	3138	as drug targets	2752
endogenous ligands in	3137	as targets for agents of anti-cancer/anti	
hematopoietic cells in	3138	other integrin related diseases	2759
lymphocytes in	3138	as targets for anti-platelet agents	2757
macrophages in	3140	as targets for drug delivery	2760
mast cells in	3142	ligands for	2724
natural killer cells in	3140	ligands for imaging/drug delivery	2733
neutrophils in	3142	ligand interaction of	2756
signal transduction associated with		structure basis for	2750
cannabinoid receptors in	3137	targeting of	2733
Immune-mediated anti-viral drugs	1391	targeting RGD based	2723
immune modulators in	1394	Intercellular adhesion molecule-1 (CAM-1)	3497
strategies for	1394	AP-1/MAP kinase regulation of	
Immunoglobulins	241	transcription of	3502
as therapeutics	241	biology of	3497
clinical trials of	246	expression for anti-inflammatory drug	
for treatment of multiple sclerosis	241	development	3504
immunomodulatory mechanisms of action of	242	GAS regulation of transcription of	3502
interaction with glial cells <i>in vitro</i>	244	inflammatory gene expressions of	3497
promotion of remyelination by	241	NF-κB regulation of	3498

- PKC-dependent C-SRC regulation of 3498
 signal transduction pathways of 3497
 therapeutic implications of 3497
 transcriptional coactivators regulation of
 transcription of 3503
- Intercellular junctions 2813
 function of 2813
 modulation of 2821
 structure of 2813
- Intracoronary radiation therapy (brachytherapy) 1283
- Invertebrates 3025
- Iodinated contrast media 3359
 chemical structure of 3359
 prevalence of hypersensitivity reactions to ... 3360
- Ionotropic glutamate receptor 3583
 pharmacological intervention at 3583
- Irinotecan 317
 as CPT-based anti-cancer drug 317
- Iron 2877
 role in ROS-induced toxicity 2877
- Iron chelation 1943
 as therapy for HIV/*Mycobacterium tuberculosis* co-infection 1943
 role in iron overload 1943
- Irritable bowel syndrome 4071
 CRF₁ receptors as therapeutic target for 4071
- Ischemia/reperfusion injury 739,2969
 mitochondria in 739
 mitochondrial changes in 741
 mitochondrial therapy for 750
 production of recombinant AD vectors for 2970
 role of antiapoptotic genes in 2970
 role of antioxidant genes in 2971
 role of cytokine antagonists in 2972
 role of immunoregulatory cytokines in 2972
 role of RNA interference in 2973
 role of T cell co-stimulation blockade in 2972
 role of transcription factor in 2972
 targets for mitochondrial protection in 744
- Isoniazid (INH) 2410
 mechanism of action of 2410
- Isoprostanes 895
 as mediators of oxidant stress 895
 as products of arachidonate peroxidation 895
 biological effects of 899
 mechanism of formation of 895
- K⁺ channel ancillary subunits 3635
 in disease 3635
- K⁺ channel blockers 2199
 IKCa1 as 2201
 immunosuppression by 2199
 Kv1.3 as 2201
 peptide blockers of 2206
 small-molecule inhibitors of 2211
 to inhibit T cell activation 2199
- K252A 2615
 as prototypic selective inhibitor of TRKA
 receptor tyrosine kinase activity 2615
- Kainate receptors 3586
- Kallikrein-kinin system 2599
 regulation of angiogenesis by 2599
- K_{ATP} channels 488
 inhibition by antidiabetic drugs 489
 metabolic regulation of 488
 molecular identity of 488
 persistent hyperinsulinemia in 493
- Kinins 3423
 effect of ACE inhibitors on 3428
 effect of angiotensin AT1 receptor
 antagonists on 3429
 in atherosclerosis 3426
 in blood pressure regulation 3426
 in cardiac contractility 3427
 in cardiovascular diseases 3423
 in coronary circulation 3427
 in heart failure 3428
 in hemostasis 3425
 in hypertension 3426
 in ischemic preconditioning 3427
 in myocardial ischemia 3427
 in regulation of renal blood flow 3427
 in water-electrolyte balance 3427
 metabolism of 3423
 transduction mechanisms of 3425
- Kv channel α subunits 2285
- Kv1.3 channels 463
- Lactoferrin 1640
- Lamivudine/emtricitabine 1081
- Leech 3034
 role of hematopoietic cells 3034
- Leishmania infantum* 4255
 human myeloid dendritic cells respond to 4255
in vitro infection with 4255
- Leukocyte adhesion molecules antagonists 3812
- Leukocyte-endothelial interaction 3799
 in animal models 3801
in vitro 3801
 mechanisms of 3799
- LFA-1/ICAM-1 2799
 based targeted therapeutic agents 2799
- Lipid abnormalities 4772
 in solid organ transplant recipients 4772
- Lipid lowering therapy 3945
 in elderly 3945
 lipid lowering in 3951
- Lipobeads 4717
 as targeted vehicles 4721
 properties of 4717

Liposomes	3821	lycopene in	601
Liposome-nanogel structures	4713	retinol in	601
pharmaceutical applications of	4713	total carotenoids in	601
Lithium	1531	vitamin A in	604
animal studies of	1533	vitamin C in	604
human studies of	1532	vitamin E in	604
in Wnt/GSK-3 pathway	1537	Lung collectins	589
mammalian studies of	1533	innate immune functions of	590
mechanisms of action on development of	1535	structural organization of	589
pharmacokinetics of	1531	Lupus erythematosus	3790
teratogenic/developmental effects of	1531	Lymphocyte function-associated antigen-1 (LFA-1)	2771
Lithium augmentation	2985	antagonists of	2777
efficacy of	2985	as regulator of immune function	2771
mechanisms of action of	2985	development of therapeutics based on	2771
Liver ischemia	2911	in human disease	2777
death receptors in	2912	in inflammation	2772
inhibition of intracellular proteases for	2915	Lysophospholipid receptors	161
intracellular targets to reduce	2917	as drug targets in tissue transplantation	161
modulators of mitochondrial cell death for ...	2914	in autoimmune diseases	161
targets for anti-apoptotic strategies in	2912	Macrophages	1835
types of	2911	mutant selection in	1835
Liver ischemia-reperfusion injury	2891,2935	Major depression	503
bucillamine in	2895	bright light therapy in	510
glutathione in	2893	CRH ₁ receptor antagonists in	508
lipoic acid in	2897	electroconvulsive therapy (ECT) in	510
mechanisms of	2937	glucocorticoid receptor antagonists in	509
<i>N</i> -acetylcysteine in	2893	inhibitors of steroid synthesis in	508
phases of	2936	magnetic seizure therapy (MST) in	511
prostaglandins (PGs) in	2939	melatonin agonists in	505
role of prostaglandins in	2935	neuroactive steroids in	509
role of thiols in	2891	pharmacological/non-pharmacological	
thioredoxin in	2895	treatment of	503
Lophotrochozoans	3043	repetitive transcranial magnetic stimulation	
innate immunity in	3043	(rTMS) in	510
Low molecular weight HSPs	888	serotonergic antidepressants in	506
α B-crystalline as	889	tachykinin receptor antagonists in	506
HSP20 as	888	total/partial sleep deprivation in	510
HSP27 as	888	vagus nerve stimulation (VNS) in	511
Lower vertebrates	3057	Male reproductive effects	1461
IL-4/IL-5/IL-9/IL-13 in	3057	evolution of guidelines for	1461
LPS signaling pathway	4126	Matrix metalloprotease inhibitors	2447
L-type calcium channels	443	Matrix metalloproteinase	2923,4458
activators of	452	in ischemia-reperfusion injury	2928
as drug target	444	in liver IR	2929
cardiovascular selectivity of action of	446	novel biology of	2926
in developments of cardiovascular drugs	449	regulation of	2927
in epilepsy	451	structure/activation of	2923
in fertility	451	Matrix metalloproteinase inhibitors	2923
targets of	450	role in ischemia-reperfusion injury in liver ...	2923
therapeutic activities of	444	Maxillary hypoplasia	1431
Lung cancer	600	and phenytoin	1431
antioxidant vitamins in	600,607	ATP depletion in	1443
α -carotene in	600	consequences of	1443
β -carotene in	600	reoxygenation damage in	1443
β -criptoxanthin in	601	MDR1	273
effect of tobacco in	607	chemosensitivity of	273
human/animal studies of carcinogenic		discovery of	273
mechanisms in	606		
lutein/zeaxanthin in	601		

- in normal tissues 275
 mediated multidrug resistance in cancer
 chemotherapy 273
 pharmacogenetics of 275
 reversal of mediated MDR by 277
 role in tumor tissues 274
 substrate specificity of 275
 suppression by chemical compounds 280
 suppression by gene modulation 280
 transcriptional regulation of expression of 274
 Mechanical device 3812
 Mechanosensitive channels 3645
 as therapeutic targets in myocardium 3645
 in cardiac muscle 3648
 pharmacology of 3651
 therapeutic targeting of 3657
 Meiosis 1489
 molecular aspects of chromosome
 segregation at 1489
Melissa officinalis 4617
 chronic administration in Alzheimer's
 disease 4619
 human behavioral studies of 4618
 mechanisms of action of 4618
 usage of 4617
 Memantine 3592
 as NMDA antagonist 3592
 Membrane (M) protein 4547
 Membrane ion channels 485
 in diabetes 485,492
 Memory systems 2511
 effect of phosphodiesterase inhibitors on 2513
 neurobiology of 2512
 role of CAMP/CGMP in 2516
 Metabolism 1421
 CYP1A in 1421
 CYP2A in 1422
 CYP2B in 1422
 CYP2C in 1423
 CYP2D in 1423
 CYP2E in 1424
 CYP3A in 1424
 total P₄₅₀ in 1421
 Metabotropic glutamate receptors (mGluRs) 2159
 allosteric binding pockets of 2170
 allosteric modulators of 2170
 crystal structure of ATD of 2166
 dynamics of activation of 2169
 homology models of ATD of 2164
 in silico approaches for 2159
 ligand based approaches for 2167
 metabotropic GABA_B receptor as 2162
 structure-function relationships in 2169,2159
 Metal cations 2150
 with non-spherical symmetry 2150
 Metastatic prostate cancer 799
 5-alpha-reductase inhibitors for 802
 androgen ablation therapy for 799
 androgen blockade vs. luteinizing hormone
 releasing hormone alone in 800
 anti-androgen monotherapy for 801
 bisphosphonates in 802
 chemotherapy for 803
 Microarray technology 3772
 for gene expression profiling 3772
 Microbicidal peptides 4209
 as prostrating/regulatory molecules
 at mucosal sites 4209
 Microreactor 4715
 liposome as 4715
 Milk 1637
 Minimal residual disease (MRD) 2306
 MinK 2291
 MiRP1 2293
 molecular determinants of 2294
 Mitochondria 739
 as target for neuroprotective interventions 739
 in cerebral ischemia-reperfusion 739
 Mitochondrial transition pore complex 4501
 peptido-targeting of 4501
 for therapeutic apoptosis induction 4501
 Modafinil 2457
 effect on cognitive performance/alertness 2457
 effects on recovery sleep/subsequent
 performance 2468
 effects on tests of executive function 2463
 in sleep deprivation 2457
 reversal of alertness impairments during
 sleep loss by 2465
 safety data of 2469
 single-dose studies of 2458
 subjective effects of 2466
 Molecular descriptors 2099,2111
 Monoclonal antibody 116,366
 mechanics of 366
 to destroy neoplastic B/T-cells 116
 Montepilase 851
 Mouse uterus 1505
 coactivators in 1506
 expression of estrogen-regulated genes
 during development in 1505
 role of Hox genes in 1510
 role of Wnt genes in 1511
 mPGES-2 950
 expression/function of 951
 structure/enzymatic property of 950
 Mucins 4204
 viscoelastic sheet formation by 4204
 Mucosal epithelium 4206
 formation of cellular junction network at 4206
 Mucosal regeneration 2404
 Multidrug resistance 287
 carotenoids in 287

natural diterpenes in	287	slow inactivation of	434
triterpenes in	287	structure of voltage sensor in	429
Multiple myeloma	327	toxin/drugs affect voltage sensing of	435
deregulation of apoptosis/proliferation in	327	$\alpha 7$ -nAChRs	3894
geranylgeranylation/regulation of		radioligands for imaging	3894
proliferation in	334	NAD ⁺ -linked 15-hydroxyprostaglandin	
geranylgeranylation/regulation of survival in ..	334	dehydrogenase	955
inhibition of mevalonate pathway in	333	biological functions of	955
mevalonate pathway in	327	structure of	955
role of anti-apoptotic BCL-2 family member		Naltrexone	1006
MCL-1 in	331	effects on insulin response to OGTT	1006
role of BCL-2 in	328	implications for management of PCOS-	
targeting BCL-2 in	327	related infertility	1008
treatment strategies for	327	modulation of pituitary function in PCOS	
Multiple sclerosis	3761	women	1008
heterogeneity of	3762	physio-pathologic mechanisms of	1007
pharmacological substances in	3774	Nanocarriers	4729
role of biological marker in	3762	for nuclear imaging	4729
role of RNA signatures in	3766	for radiotherapy of cancer	4729
therapy monitoring based on gene		Nanogels	4704,4716
expression	3761	properties of	4716
Muramyldipeptide (MDP)	4163	synthesis of	4704
in osteoclast formation induced by LPS	4166	vectorization of	4705
<i>in vivo</i> studies in mice	4164	Nanomedicine	4751
Muscarinic acetylcholine receptors	3573	Natural products	3504
function of	3577	Neoadjuvant androgen deprivation (NHT)	799
regulation of	3575	early vs. late	800
structural understanding of	3574	in localized prostate cancer treatments	799
subtypes delineated by gene targeting		intermittent vs. continuous	801
technique	3577	Neovascularization	557
therapeutic drugs targeting of	3578	mechanisms of	557
Muscarinic receptor	3901	Nerve growth factor (NGF)	2609
clinical management	3909	angiogenic effects of	2609,2614
imaging in central nervous system	3901	angiogenic/neurotrophic effects of	2616
<i>in vitro/in vivo</i> binding of	3902	implications in drug development	2609
radionuclides for	3901	neuronal effects of	2614
subtype selectivity of	3906	receptor structure of	2613
tracer principle to study	3901	signaling of	2613
use of knock-out mice to subtype		Neuroblastoma	2303
specificity of	3907	angiogenesis as target for	2310
Mutagenesis	2093	differentiation/apoptotic therapy for	2307
<i>Mycobacterium tuberculosis</i>	1943,2409	gene expression profiling in	2311
effect of inorganic complex	2409	gene therapy for	2309
<i>in vitro</i> analysis of excess iron on		genetic abnormalities in	2305
infection in	1944	immunotherapy for	2308
iron chelators in	1945	molecularly guided therapy of	2303
slow-onset inhibition of 2- <i>trans</i> -enoyl-ACP		role of <i>MYCN</i> gene amplification in	2304
(CoA) reductase from	2409	Neurodegeneration	3521
Mycophenolate mofetil (MMF)	1124	dual effects of antioxidants in	3521
MYD88	4127	Neurodegenerative diseases	705,3509,3526
Myocardium	3645	anti-inflammatory drugs in	3509
Na ⁺ channel	429	glia mediated inflammation in	3526
activation-inactivation coupling of	434	treatment of	3509
fast inactivation of	433	Neuronal KCNQ-derived channels	463
isoforms of	429	Neuronal nicotinic acetylcholine receptor	
molecular mechanisms of gating of	429	(nAChRs)	3877
pharmacology of	429	$\alpha 4\beta 2$ a-nAChR radioligands for imaging	
site-dependent action of toxin/drugs on	436		

- extrathalamic based 3888
- development of radioligands for 3877,3880
- in human brain 3877
- in vivo* imaging of 3877
- PET radioligands based on 3-pyridyl
 - ethers for 3880
 - properties of radioligands for 3878
 - radiochemistry of radioligands for
 - imaging of 3895
 - role of PET/SPECT in 3877
- Neuronal nicotinic receptors 407
 - agonists of 412
 - allosteric modulators of 417
 - antagonists of 414
 - as targets for drug discovery 407
 - as targets pathology 420
 - binding sites of 407
 - α bungarotoxin insensitive 410
 - α bungarotoxin sensitive 409
 - drugs affecting function of 411
 - function of 409
 - in development/aging 410
 - localization of 408
 - molecular structure of 409
 - regulation by long term-exposure to
 - nicotinic agents 418
 - transition states of 412
- Neuroprotection 3521
 - against oxidative stress 3521
 - protection *via* suppression of glia mediated
 - inflammation in 3521
- Neuropsychology 2525
- Nevirapine 1082
- NF- κ B 3498
- Nitregic modulation 4525
 - during early endotoxemia 4525
 - of gastrointestinal function 4525
- Nitric oxide 3221,3543,4445,4527
 - biochemistry of 4445
 - biology of 3543
 - chemistry of 4445
 - in asthma therapy 3221
 - in hemorrhagic shock 3546
 - physiology of 4445
 - production of 3222
 - properties of scavengers of 3544
 - role in apoptosis 4448
 - scavenging compounds of 3544
 - targets for 3223
 - therapeutic opportunities for 3225
- Nitrosative stresses 3523
- NMR 3963
 - labeling by 3969
- Nociception 23
- Non-Hodgkin's lymphoma 334
 - modulation of mevalonate pathway in 334
- Nonnucleoside HIV-1 reverse transcriptase
 - inhibitors 1857
 - design of 1861
- development of resistance to 1858
- history of 1857
- mechanism of 1859
- Non-nucleoside molecules 1347
 - inhibition of DNA Pol by 1347
- Non-nucleoside reverse transcriptase
 - inhibitors 1081,1886
 - dermatologic adverse reactions by 1081
 - dimerization destabilizers as 1888
 - dimerization inhibitors as 1889
 - hepatotoxicity by 1081
- Non-ring helicases 1323
 - mechanism of action of 1323
- Norepinephrine transporter (NET) 3831
 - PET imaging of 3831
 - in depression 3832
 - in neurodegenerative disorders 3832
 - in ADHD 3832
 - in substance abuse 3833
 - radioligands for *in vivo* imaging of 3836
 - in occupancy studies 3839
- Novel nicotinic agonists 414
 - as analgesics 414
- NRTIs 1874
 - implications for design of 1875
 - resistance conferring mutations of 1874
- NSAID 3347,4328
 - as γ -secretase inhibitors 4328
 - cells in hypersensitivity to 3348
 - cross reactivity of 3349
- Nuclear magnetic resonance (NMR) spectroscopy ...4023
 - in determination of absolute configuration ...4035
 - in determinations of enantiomeric purities ...4023
 - in investigation of enantio-recognition 4036
- Nuclear receptors 1723
 - as druggable gene family 1723
- Nucleic acid-based antiviral agents 1995
 - by aerosolization 1997
 - delivery of 1995
 - immunopotentiating reconstituted influenza
 - virosomes (IRIVS) for 1999
 - liposomes for 1995
 - nanoparticles for 1998
 - retrovirus based vectors for 2001
 - stability of 1996
 - transfection efficiency of 1997
 - viral vectors for 1999
- Nucleocapsid (N) protein 4544
- Nucleoside analogs 1345
 - inhibition of HBV polymerase activity by 1345
- Nucleoside analogues 1347
 - to inhibit herpesvirus DNA Pol 1347
- Nucleoside analogues 1817
 - cross-reactivity with 1817
- Nucleoside/tide reverse transcriptase inhibitors 1076
 - lactic acidosis by 1077
 - lipatrophy by 1076

mitochondrial toxicity by	1076	PDE7A inhibitors	3214
peripheral neuropathy by	1078	PDE7A1	3210
Nucleus	4434	expression of	3210
effects of ROS in	4434	PDE7A2/PDE7A3	3210
		expression of	3210
Omalizumab	3929	PDE7B variants	3211
clinical studies of	3941	regulation of	3211
in clinical development	3934	Penicillins	3327
Open-shell divalent cation	2149	immediate hypersensitivity reactions to	3327
Opioid antagonists	1001	Peptide affinity ligands	194
in hyperinsulinemia	1002	preparation of	194
in menopause	1003	screening procedures for	194
in polycystic ovary syndrome	1003	Peptidoglycans (PGNs)	4163
in treatment of women with glucoregulation		intracellular receptors of	4163
abnormalities	1001	Periodontal regeneration	2402
inhibition of opioid tone in post-		Peripheral anionic site	217
menopausal patients by	1009	as matrix binding sites	221
Organogenesis	1442	binding inhibitors of	219
embryo on oxygen during	1442	protein association at	220
Osteoarthritis	639	role in catalysis	219
chondroitin sulfate analysis in	639	structure of	218
pharmacological treatment of	639	Permeability transition pore (PTPC)	4501
1,2,4-Oxadiazolin-5-ones	81	as therapeutic target	4503
as prodrugs of amidines	81	peptido-targeting of	4506
Oxidative stress	900,2875,3524	Peroxynitrite	2903
chelating compounds in	2875	PET	3831
in neurodegenerative diseases	3524	characteristics of ideal tracer of	3833
modulating IsoP formation action for	900	in kinetic modeling	3834
pharmacological approaches to	900	PGE2	3349
reactive oxygen species in	2876	as brake of cellular activation	3349
Oxygen free radical scavengers	3812	PGI ₂ synthase	925
		cloning/enzymatic properties of	925
Pain	2192	substrate access channel topology of	927
anesthetics/analgesics for	2193	Pharmaceutical design	1403
behavioral studies in	2193	drug diffusion models in	1409
role of T-type channels in	2192	macroscopic hydrogels in	1404
Paracellular drug delivery	2813	micor/nano-particles in	1413
barrier of	2813	microbubbles in	1415
role of tight junction (TJ) plaque		microfabricated drug delivery systems in	1416
proteins in	2816	microfluidic devices in	1416
tight junctions in	2814	soft condensed matter in	1403
Parkinson disease (PD)	2563	Pharmacogenetics	2425
Pathogen-associated molecular patterns (PAM)	4155	of drugs	2429
invertebrate innate immune recognition		of statins	2430
of (1→3)-β-D-glucan as	4155	Pharmacogenomics	1134,3195
molecular basis for	4155	whole-genome approaches in	3201
Pattern recognition receptors	4173	Pharmacokinetic (PK)	1129
PDC infrastructure	4789	of entry inhibitors	1132
PDE5A3 isoform	3443	of non-nucleoside reverse transcriptase	
in RAT	3443	inhibitors	1130
PDE7	3207,3208	of nucleoside reverse transcriptase inhibitors	1129
discovery of	3207	of protease inhibitors	1132
gene structure of	3208	role of cytochrome P ₄₅₀ isoforms in	1134
heterogeneity of	3208	role of P-glycoprotein in	1136

- Pharmacological CDK inhibitors1360,1949
 act on HSV-1 regulatory proteins/HSV-1
 DNA synthesis 1365
 antiviral activities of 1362
 as anti-HIV therapeutics 1949
 cellular targets of 1365
 clinical tests of 1366
 for drug resistant HSV-1 mutants 1364
 genome-wide analysis of inhibitory
 mechanism of 1955
 mechanisms of inhibition of viral
 transcription by 1363
 target viral gene expression of 1363
 to prevent reactivation of latent HSV 1364
- Phenytoin 1431
 exposure in pregnancy 1431
 teratogenesis by 1443
- Pheromones 3015
 biology of 3015
 cytoplasmic precursors of 3017
 of protozoan ciliates 3015
 physicochemical features of 3017
 primary structures of 3017
 sources/secretion of 3016
 three-dimensional conformations of 3017
- Phosphodiesterases2511,3459
 effect on memory 2511
 X-ray crystal structure of 3460
- Phosphodiesterase 53439
 allosteric binding-induced activation of 3444
 cleavage by caspase-3 3446
 cloning/sequences of isoforms of 3441
 deactivation/inhibition of 3445
 distribution of 3439
 expression of 3439
 gene/promoters of 3452
 identification/structure of 3441
 phosphorylation-induced activation of 3443
 physiological/pathological roles of 3440
 regulation of 3439
 regulation of expression of 3452
 regulation of function of 3443
 tissue/cellular expression of 3446
 tissue/cellular expression of isoforms of 3449
- Phosphodiesterase 5 inhibitors3467,3485
 cardiovascular effects of 3485
 clinical use of 3475
 effect on cardiovascular system 3488
 mechanisms of 3486
 patho-physiology of 3486
 pharmacology of 3486
- Phosphodiesterase 5 inhibitors 3459
 differentiation based on selectivity of 3459
 drug design of 3459
 efficacy profiles of 3459
 pharmacokinetic of 3459
 pharmacology/pharmacokinetics of 3464
- Phosphodiesterase 7A 3207
 as therapeutic target for alleviating chronic
 inflammation 3207
 distribution in cells relevant to chronic
 inflammation 3211
- Phylogenetic tree2998
 of animals3004
 organization of3002
 roots of2998
- Phylogeny2997
 genetic code in2997
- Picornavirus 1305,1379
 experimental therapies for1386
 targets for chemotherapy of1379
 virology of1379
- Plasma membrane4435
 ROS generation in4435
- Platelets887
 physiological effects of low molecular
 weight HSPs on887
- Platelet adenosine diphosphate receptors1261
- Platelet-derived growth factor (PDGF)3025
 role of3026
- Platelet GPIIb/IIIa receptor antagonists79
 prodrugs of79
- Poly (ADP-ribose) polymerase pathways2903
 in liver injury2908
 in pathogenesis of hepatic damage
 associated with circulatory shock2906
 in pathogenesis of liver injury2903
- Polyglutamine (polyQ)2543
 misfolding/aggregation/toxicity of2544
 structure of2544
- Polyglutamine diseases2543
 induction of heat shock response in2549
 inhibition of misfolding/aggregation for2546
 mechanisms of2550
 protein misfolding/aggregation in2543
 strategies for therapy of2545
 targeting neuronal cell death for2549
 therapeutic approaches to2543
- Polymerase translocation1867
 drug action at1867
 effects of nucleotides/nucleotide analogue
 inhibitors of HIV-1 reverse transcriptase in1867
 models for1869
 models of HIV-1 reverse transcriptase1871
 ratchet model of1867
- Polymer-drug conjugates4794
 in clinical trials4794
- Polymeric micelles4669
 advantages/applications of4673
 block copolymer classes of4676
 for drug delivery4669
 physical properties of4670
- Porcine cytochrome P4501421
 in metabolism1421
- Postassium channels459
 modulation of459
 modulators of460
 therapeutic approach by using459

Post-ischemic microcirculation	3808	expression/function of	945
functional changes of	3808	in Alzheimer's disease	948
structural changes of	3808	in ductus arteriosus closure	949
Potassium channel openers	3811	in fever	947
PPAR- γ	93	in gastrointestinal homeostasis	948
characteristics of	94	in inflammation	946
in brain inflammation	99	in renal homeostasis	948
in microglial cells	99	in reproduction	948
in multiple sclerosis	104	in tumorigenesis	947
in neurodegenerative diseases	103	structure of	943
ligands for	95	transcriptional regulation of	944
structure of	94	Prostanoids	2375
PPAR- γ agonists	93	for cancer chemoprevention	2375
as regulators of microglial activation	93	in colon carcinogenesis	2375
in brain inflammation	93	Prostate cancer	785,807,819,1923
in multiple sclerosis	104	active immunotherapy for	811
in neurodegenerative diseases	103	adoptive immunotherapy for	810
synthetic type	96	after prior local therapy	785
PPAR- γ antagonists	98	5-alpha-reductase inhibitors for	794
Pregnancy	1432	alternative treatments for	830
cigarette smoking during	1432	antiandrogen monotherapy for	792
corticosteroid exposure in	1432	bisphosphonates for	830
living at high altitude during	1432	carbohydrate/protein vaccination for	811
Primary immunodeficiency diseases	549	chemotherapy for	819
as candidates for gene therapy	550	cytokine therapy for	812
gene therapy for	549	diagnostic evaluation of	787
natural gene therapy for	550	early single agent trials for	819
Prion disease	2562,2587	estramustine trials for	824
β -sheet breakers for	2562	gene therapy for	813
role of copper in	2587	herbal therapies for	835
Pro-inflammatory	3822	immunotherapy for	807
Pro-inflammatory cytokines	3083	management of biochemical recurrence in	789
Pro-oxidant milieu blunts scissors	4469	mitoxantrone for	824
in drug resistance	4469	monoclonal antibodies for	808
in tumor progression	4469	natural/synthetic retinoids in	1923
role in novel druggable targets	4469	passive immunotherapy for	808
Prostacyclin	208,925	radionucleotide therapy for	826
biosynthesis of	925	small cell variant for	826
implications of molecular basis of	925	steroids for	819
implications of pharmaceutical designs		target antigens in	808
targeting	933	taxanes for	825
in gastrointestinal system	936	traditional hormonal therapy for	791
in obesity	936	treatment of	785
in pulmonary arterial hypertension	933	Prostate specific antigen (PSA)	785
in reproductive system	936	Protease inhibitors	1082
in vascular diseases	934	effect on lipids	1083
molecular basis of	929	gastrointestinal effects of	1082
signaling in pharmaceutical designs	925	hyperglycemia by	1084
signaling <i>via</i> nuclear peroxisome		lipoaccumulation by	1084
proliferator-activated receptors	932	metabolic changes by	1083
signaling <i>via</i> plasma membrane		Proteasome inhibitors	120
receptor	929	Protein	2067,3963
Prostaglandins	2935	assembly methods for	2072
in ischemia/reperfusion (IR)	2936	assessment of function prediction of	2079
Prostaglandin E synthase	943	CASP experiment for	2068
as drug target for inflammation/cancer	943	chemical shift perturbation of	3964
μ class of	951	comparative modeling for	2069
enzymatic property of	943	consensus methods for	2070
		fold recognition for	2070
		function from sequence	2067
		function/function-structure relationship of	2074
		functional descriptors from structure of	2077

- in vitro* labeling of 3965
in vivo labeling of 3965
 intrinsic disorder of 2070
 labeling of 3965
 large-scale prediction of 2067
 model quality estimation of 2073
 predicting structure from sequence of 2068
 profile-profile alignments of 2072
 SAR by NMR 3964
 structural genomics for 2067
 structural information in alignments of 2072
 structure comparison of 2077
 template detection in 2071
- Protein kinase C isoenzymes** 3117
 activity on immunity/B cell tolerance 3128
 activity on myocardium 3127
 carcinogenic activity of 3123
 cardioprotective activity of 3127
 distinctive cellular roles for 3117
 genomic structures of 3117
 immunoprotective activity of 3128
 in apoptosis 3126
 in cellular differentiation 3125
 in regulation of cell proliferation 3124
 maturation of 3120
 oncogenic activity of 3122
 proteomic structure of 3118
 tumor-suppressor activity of 3123
 upstream effectors for 3121
- Protein microarrays** 3735
 applications of 3735
 bioinformatical analysis of 3739
- Protein misfolding/aggregation** 2557
 effect of small rationally-designed peptides .. 2558
 mechanism of 2557
- Protein/protein interactions** 529
 effect of drugs on 529
 of CrK family adaptors 529
- Proteomics** 3699
 in human fluids/tissues 3700
- Protooncogenes** 1512
 expression of estrogen-regulated 1512
- Protostomes** 3008
- PrP^c** 2588
 as copper binding protein 2588
- PS/γ-secretase complex** 663
 assembly of 663
 molecular composition of 663
- PSA/TRICOM** 359
- Psoriasis** 989,3787
 administration of anti-inflammatory cytokines/
 induction of immunodeviation for 995
 alefacept (LFA-3TIP) for 990
 biological dramatic advances in 989
 CTLA4-Ig (BMS 18667) for 991
 efalizumab (hu-1124) for 991
 elimination of activated T-cells for 992
 IDEC-114 for 992
 inhibition of adhesion of inflammatory
 cells for 993
 inhibition of effect of proinflammatory
 cytokines/mediators for 994
 inhibition of T-cell activation for 990
 inhibition of T-lymphocyte extravasation for .. 993
 OKTcdr4a for 992
 treatment of 989
- Psychopharmacology** 2527,4613
 of attention/cognition 2527
 of European herbs with cognition-
 enhancing properties 4613
 of *Melissa officinalis* 4617
 of *Rosemarinus officinalis* 4619
 of *Salvia officinalis* 4614
- Pulmonary fibrosis** 2694
 roles of GM-CSF/G-CSF in 2694
- Pulmonary surfactant proteins A/D** 589
 clinical application as biomarkers 593
 in biomarkers for lung diseases 589
 innate immune functions of 589
- Purinergic receptors** 859
 classification of 859
 pharmacology of 860
- Quantitative structure-activity relationships
 (QSAR)** 4601
 applications in rational drug design 4601
 ligand-receptor interactions in 4604
 with computational techniques 4607
- Quinolones** 3313
 crossreactivity of 3320
 hypersensitivity reactions by 3313,3315
 immediate adverse reactions by 3316
 interaction with T cells 3320
 mode of action of 3313
 non-IgE mediated delayed-adverse
 reactions of 3317
 structure of 3313
 structure-activity relationship of 3314
- Radionuclides** 4732
 chelating agents for 4732
 nanocarriers for delivery of 4733
- Rare diseases** 1171
 major problems of 1171
- Rational drug design** 4601
 development of molecular descriptors for
 2D-QSAR in 4602
- Receptorome** 1785
- Receptoromics** 1785
- Recombinant human polyclonal antibodies** 2007
 against HIV 2009
 against orthopox viruses 2010
 against RSV 2011
 as therapeutic antibodies against viral
 infections 2007
 rules for designing of 2008

Redox homeostasis	4470	protease inhibitors for	1380
Reductase inhibitors	775	viral RNA synthesis inhibitors for	1381
development of	775	Rifamycin derivatives	4051
Refractory major depression	2985	Ring helicase	1327
lithium augmentation in	2985	mechanism of action of	1327
Refractory multiple myeloma	334	Ritonavir	1085
modulation of mevalonate pathway in	334	Rituximab	113
Regenerative medicine	2397	RNA virus-based vectors	2001
applications in Alzheimer's diseases/ Parkinson's disease/multiple sclerosis	2399	Rosemary	4619
clinical delivery systems of	2401	human investigations of	4620
hematopoiesis/stem cells in	2399	mechanisms of action of	4620
therapeutic modulation of growth factors/ cytokines in	2397	usage of	4620
Remyelination	241	RT inhibitors	1812
Renal epithelial sodium channel	2221	acquisition of resistance to	1812
effect of serum/glucocorticoid induced kinase (SGK) on	2225	<i>Salvia officinalis</i>	4614
genetic heterogeneity of	2221	acute behavioral studies of	4616
Nedd4-2 as	2224	cholinesterase inhibition by	4615
physiological role in blood pressure regulation	2227	usage of	4615
regulation of	2223	SARS 3C-like proteinase	4555
structural characteristics of	2222	catalytic mechanism of	4556
treatment of high blood pressure by	2221	inhibitor discovery for	4558
Reperfusion injury	2903	inhibitors design for	4555
role of PARP in	2903	quaternary structure of	4555,4556
Reproductive tract	1506	substrate selectivity of	4555
malformations of	1506	substrate specificity of	4557
Reproductive/developmental toxicology	1449	SARS coronavirus (SARS_CoV)	4539,4565
guidelines for	1449	bioinformatics research on	4565
ICH study designs for	1458	drug development of	4539
risk evaluation of	1455	functional genomics studies on	4566
Retinoids	1923	functions of	4539
in human cancer	1926	genome-encoded major proteins of	4539
in prostate cancer	1926	in China	4565
mechanism of action of	1923	major proteins encoded by	4540
physiological role in prostate	1925	molecular evolution of	4568
Retroviral vectors	549	structures of	4539
hematopoietic stem cell gene therapy using	549	transmission models of	4570
RGD	2734,2749	Schizophrenia	2533
based imaging agents	2734	cognitive domains for	2533
containing snake venom toxins	2756	Second-generation MDR modulators	278
labeled compounds for drug targeting	2735	γ -Secretase	661,4321
Rheumatic diseases	3553	and role of PS complex	661
oxygen radical generation in	3553	as therapeutic target	661
production of nitric oxide (NO) in	3553	for treatment of Alzheimer's disease	661
Rheumatoid arthritis (RA)	2631,3753	inhibitors design of	4324
angiogenesis in	2633	mediated proteolysis-dependent signaling/ degradation	663
anti-angiogenic therapy in	2635	problematic of	4323
genetic basis of	3753	proteolytic processing of APP by	661
in mouse models	3753	Sensory nerves	2978
Rhinoviruses	1380	effect on healing of chronic gastric ulcers	2980
capsid binder inhibitors for	1381	effect on restitution	2978
clinical studies of	1382	Sepsis	3543
experimental therapies for	1380	nitric oxide scavengers in	3543
innovative inhibitors for	1381	Septic shock	3535
		animal studies of	3535

- clinical relevance of 3536
 clinical trials for 3535
 therapies of 3535
 traditional therapy for 3536
 Serotonin 2473
 clinical aspects of 2478
 effect on human cognitive performance 2473
 in neurodegeneration 2480
 Seven-transmembrane-domain receptors 1683
 ERK1/2 coupling with 1696
 mechanisms of ERK1/2 regulation by 1683
 receptor tyrosine kinase transactivation by ... 1692
 role in temporal/spatial signaling controls ... 1696
 SH2 domain interactions 531
 of CrK 531
 of CRKL 531
 of Gab proteins 532
 of p130Cas 531
 of paxillin 532
 Shock 3543
 nitric oxide scavengers in 3543
 NO scavengers in 3545
 Sigma receptor ligands 3857
 as PET radiopharmaceuticals 3865
 as radiopharmaceuticals 3857
 as SPECT radiopharmaceuticals 3868,3871
 as therapeutic drugs 3857
 clinical application of 3869
 in cancer 3864
 in cocaine addiction 3863
 in cognition 3862
 in depression 3859
 in development of radiopharmaceuticals 3865
 in ischemia 3860
 therapeutic application of 3858
 SK_{Ca} channels 466
 Skeletal muscle 2057
 effect of ACE on 2057
 Skeletal tissue regeneration 2400
 sm TLR4 4145
 Small envelope (E) protein 4547
 Small molecule inhibitors 1886
 Small molecule VEGFR kinase inhibitors 390
 Small rationally-designed peptides 2557
 inhibition of protein misfolding/
 aggregation by 2557
 Soft condensed matter devices 1403
 for efficient drug delivery 1403
 Solid tumor 379,389
 differentiation by differentiation inducers 379
 differentiation-inducing therapy for 379
 PPAR γ as differentiation inducing drug for ... 380
 VEGF inhibitors in treatment of 389
 Soluble VEGF receptor 391
 Sphingolipids 4627
 biological functions of 4627
 Sphingosine 1-phosphate 575
 effects on ECs 578
 effects on platelets 577
 effects on SMCs 580
 in plasma 575
 in vascular biology 575
 regulation of 577
 regulation of biological activities of 581
 role in cerebral vasospasm 584
 role in ischemic heart diseases 584
 role in manipulation of angiogenesis 583
 therapeutical implications of 581
 Sphingosine-1-phosphate/ceramide balance 4625
 approach for tumor therapy 4625
 generation/degradation of 4625
 Statins 726,1271,1594,4771
 clinical trials of 726
 drug-drug interaction of 1271
 effect on coagulation/fibrinolysis 1599
 effect on endothelium 1595
 effect on inflammation 1598
 effect on intimal medial thickness (IMT) 1601
 effect on platelets 1595
 effects of treatment on hypertension 1605
 effects on endothelium 1597
 in coagulation 1595
 in fibrinolysis 1595
 in inflammation 726,1595
 in pediatric/adolescent transplant recipients ..4777
 mechanism of action of 4773
 pleiotropic effects of 1594
 role in solid organ transplantation 4771
 studies in solid organ transplantation 4774
 trials in dyslipidemia 1602
 trials in patients with hypertension 1603
 Stavudine 1079
 Stem cells 2401,4766
 applications of 2401
 engineering of 4766
 Stent thrombosis 1281
 pathophysiology of 1281
 Stress-related visceral hyperalgesia 4079
 role of CRF₁ receptors in 4079
 Stroke 1293
 aspirin in 1294
 clopidogrel in 1294
 dipyridamole plus aspirin in 1295
 Structural biology 2087
 in initial lead discovery 2088
 in lead optimization 2091
 in target selection 2088
 SU-5416 2611
 as prototypic selective inhibitor of tyrosine
 kinase activity of VEGFR2 2611
 Sulphonylureas 489
 clinical implications to block 490
 properties to block K_{ATP} channels 490
 Surface plasmon resonance biosensor 4000
 applications of 4011

based interaction analysis	4002	Third-generation MDR modulators	279
in biopharmaceuticals	4011	Thrombin	75,888
in small synthetic drug molecules	4012	inhibitors of	75,82
Sweet taste inhibitor	4596	platelet aggregation induced by	888
hT1R3's TMD binding site for	4596	Thromboxane A ₂	903
Sweet taste receptor	4591	and isoprostanes	906
amino terminal domains of	4593	metabolism of	903
cysteine-rich domain of	4594	physiological/pathological roles of	903
heterodimeric based	4591	receptor for	905
homology model of	4596	Thromboxane modulators	903
ligand binding sites of	4591	clinical application of	903
modeling structure of	4592	design/chemical properties of	903,906,915
transmembrane domain of	4596	in patho-physiological states	911
Systemic scleroderma	3791	therapeutic application of	916
T cell polarization	4247	Thromboxane receptor antagonists (TXRAS)	907
therapeutic control of	4247	Thromboxane synthase	904
T cells	132,3318	Thromboxane synthase inhibitors (TXSIS)	907
in effector immunological synapse	136	Thrombus	1289
self-non self distinction by	132	detection of	1289
to recognize small chemicals/drugs like		formation of	1289
quinolones	3318	Tipranavir	1086
T helper-1 (TH1) cell cytokines	3051	Tissue factors/factor VIIa inhibitors	86
T helper-2 (TH2) cell cytokines	3055	Tissue regeneration	2398
T regulatory (T _R) cell cytokines	3060	vascular/hematopoietic based	2398
T1 interleukins	3085	Tissues	3819
T2 interleukins	3087	electric field distribution in	3819
T3 interleukins	3087	TLR2	4185
Target organ damage	1581	TLR4	4185,4229
changes in matrix metalloproteinases	1586	in atherosclerosis	4231
hypertensive renal disease as	1584	in respiratory response to endotoxin	4185
hypertensive retinopathy as	1583	in vascular inflammation	4229
implications for drug therapy	1581	signaling of	4229
in hypertension	1581	therapeutic targets of	4235
molecular mechanisms of	1584	Tolerance induction	149
pathophysiology of	1581	CD28/CTLA-4/B7 costimulatory pathway in ..	149
Tenofovir	1079	mechanisms of CTLA-4-Ig in	149
TGF- β family	877	Toll-like receptor	2365,4123,4173,4195,4207,4247
cellular signal transduction mechanism of	881	adapter proteins for	4127
modulation of cellular signal transduction of ..	877	adaptive immune response by	4128
TGF- β receptors	342	and fungi	4179
signaling of	342	and parasites	4180
Thalidomide	121	and virus	4178
Thienopyridine	1281	as pattern recognition receptors	4195
after coronary interventions	1284	as receptor for microbial ligands	4124
and drug eluting stents	1282	association in regulation of gut innate	
in percutaneous coronary interventions	1281	immunity/intestinal epithelial homeostasis ..	4220
treatment in non-elective coronary		based ligands cause sterile inflammation	4130
interventions	1283	biological function of	4174
Thienopyridines	1257,1271	CD14/CD36 as co-receptors for	4127
drug-drug interaction of	1271	cell type specific expression of	4136
pharmacokinetic/pharmacodynamics of	1257	dependent/independent signaling	
Thiols	2891	pathways in DCS	4250
		effect of activation/blockade	4123
		expression/distribution in	
		gastrointestinal tract	4217
		for mucosal protection/symbiosis	4207
		forward/reverse genetic analysis of	4124

- in bacterial infections4177
 in dendritic cell activation4247
 in gastrointestinal inflammation4215,4221
 in human infections diseases4173
 in leprosy4177
 in pathogenesis of IBD4220
 in recognition of pathogens42
 in tuberculosis4178
 intracellular localization of4136
 mediated innate immune responses4163
 molecular bases for diversity in signaling of4248
 negative regulators signaling of4138
 NOD signaling of4163
 positive cells of4255
 recognition of *Aspergillus fumigatus* by4196
 recognition of *Candida albicans* by4195
 recognition of *Cryptococcus neoformans* by4197
 recognition of fungal pathogens by4195
 recognition of other fungi by4198
 role of peptidoglycans4163
 signaling in pathogenesis of asthma2367
 signaling mechanisms of4123,4174,4247
 signaling *via* distinct adaptor molecules4137
 stimulation of signaling of4131
 synergistic activity between
 NOD ligands and4166
 therapeutic application of agonists of4138
 therapeutic application of antagonists of4138
 therapeutic targeting of4215
- Toll-like receptor 44143
 MD-28 in4145
 mediated macrophage inflammatory
 response4143
 negative regulators of4143
 regulation of signaling of4144
 role of IRAK-M4147
 role of MKP-14147
 role of MyD88s4147
 role of SOCS4147
 role of Tollip4146
 signaling of4143
- Toxins2749
 integrins in drug targeting-RGD templates in 2749
- t-PA (alteplase)849
 releaser from vascular endothelial cells853
- Transcription factors4434
 redox modulation of4434
- Transforming growth factor- β (TGF)- β 341,1195,3025
 activation of341
 as molecular target for therapy of
 glioblastoma341
 as regulator of immune system1196
 autocrine/paracrine effects on glioma cells343
 biological effects of342
 in hepatogastrointestinal diseases1197
 in tumorigenesis1197
 pharmacological inhibitors synthesis of345
 release of341
 role of3026
 synthesis of341
- Transmissible spongiform encephalopathies2562
- Transplant rejection2383
 mechanisms of2383
 pharmacological modulation of cytokines in 2383
 therapeutic management of2383
- Transplantation2390,4777
 combination therapy in4777
 role of arachidonic acid metabolites in2390
- Traumatic brain injury1645
 altered neurotransmission after1659
 AMPA/KA receptor modulation in1650
 anticonvulsants for1663
 anti-inflammatory compounds for1654
 attenuation of excitotoxicity in1649
 bradykinin modulators for1656
 calcium channel blockers for1651
 CDP-choline for1653
 citicholine for1653
 controlled cortical impact for1646
 cyclooxygenase inhibitors for1655
 deferoxamine for1652
 endocrinological treatment approaches to1658
 experimental models of1645
 inhibition of intravascular coagulation for1663
 inhibitors of glutamate release for1651
 inhibitors of nitric oxide synthases for1654
 lateral fluid percussion for1645
 LY431122 for1652
 metabotropic receptor modulation in1651
 NMDA receptor antagonists for1649
 pharmacological inhibition of calcium
 channel for1651
 pharmacological inhibition of calpains for1657
 pharmacological inhibition of caspases/
 proapoptotic cascades for1656
 pharmacological treatment of1645,1649
 role of acetylcholine in1660
 role of adenosine in1664
 role of BDNF in1662
 role of catecholamines in1660
 role of cytokines in1655
 role of DHEAS/DHEA in1658
 role of estrogen in1659
 role of GABAergic system in1661
 role of GDNF in1663
 role of glucocorticoids in1658
 role of growth hormone/insulin like growth
 factor-1 axis in1658
 role of histamine in1660
 role of immunophilin ligands cyclosporin A/
 tacrolimus in1664
 role of neurotrophins in1662
 role of NGF in1662
 role of NT-3 in1662
 role of NT4/5 in1662
 role of PARP in1664
 role of progesterone in1659
 role of serotonin in1660
 role of TRH analogs in1659
 tirilazad/pyrroloyrimidines for1652
 vitamin E for1652
- TRIad of COstimulatory Molecules (TRICOM)351
 clinical trials of vaccines based on359
 in vitro353
 in vivo353

intratumoral vaccination with	357	in HIV therapy	981
quality of T-cells generated by	358	in pharmacokinetic/pharmacodynamics	977
tumor prevention studies of	356	in therapy	977
Triterpenoids	287	PD considerations of	981
MDR reversal effect on mouse lymphoma		PK considerations of	979
cell line	288	Urbilateria	3005
TSAO derivatives	1895	problem of	3005
as family of NNRTIS	1898	Urocortins	4072
as inhibitors of HIV-1 reverse transcriptase		gastrointestinal distribution of	4072
dimerization	1895	Vaccine development	1391
as reverse transcriptase inhibitors	1896	chimeric yellow fever virus-based	1395
dimerization of	1899	DNA-based	1394
effect on HIV-1 encoded reverse		recombinant vaccinia-based	1395
transcriptase	1895	Vascular diseases	575
to inhibit HIV-1 reverse transcriptase	1903	therapeutic strategies to control	575
T-type calcium channels	2189	Vascular endothelial growth factor	
in dorsal horn	2193	(VEGF)	387,843,2609
in epilepsy	2189	angiogenic effects in nervous system	2611
in nociceptive neurons	2192	angiogenic/neurotrophic effects of	2616
in pain	2189	implications in drug development	2609
nociceptor excitability by	2193	interaction with α 2-AP	843
physiological roles of	2189	monoclonal antibodies against	389
Tuberculosis	2409	neuronal effects in nervous system	2611
chemotherapy for	2410	neurotrophic effects of	2609
INH analogs for	2411	regulation of reendothelialization by	
Tumor	357,2303,2723,4437,4628	α 2-AP <i>via</i>	844
clinical aspects of targeting S1P in	4628	Vasoconstrictors	4637
imaging of	2723	Vesnarinone	380
irradiation of	357	as anti-cancer agents	382
redox metabolism in	4437	biological activity of	380
Tumor angiogenesis	2661	effect on growth of leukemia cells	382
data analyses/post-processing of	2665	effect on growth of solid tumor cells <i>in vitro</i>	381
imaging of	2661	effect on growth of solid tumor <i>in vivo</i>	382
of apoptosis	2665	molecular structure of	380
of necrosis	2665	Vessels	3033
of tumor hypoxia	2665	development of	3033
Tumor microenvironment	2833	Viral disease	2008
adhesion dependent signaling in	2833	antibody therapeutics in	2008
cadherin adhesion molecules in	2835	recombinant human polyclonal anti-	
CD44 adhesion molecules in	2836	bodies in	2008
drug targeting for	2833	Viral helicase	1316
immunoglobulin superfamily adhesion		classification of	1316
molecules in	2836	flavivirus helicases as	1321
integrin adhesion molecules in	2833	hepatitis C virus NS3 helicase as	1320
mechanisms of drug resistance in	2836	human papillomaviruses helicase as	1322
selectin adhesion molecules in	2836	properties of	1317
Tumor necrosis factors α	4271	SARS coronavirus helicase as	1320
suppression of <i>in vivo</i> production of	4274	Viral proteases	1301
Tumour cells	4414,4453,4458	antiviral drug discovery targeting to	1301
apoptosis regulating molecules affected by		drug development based on	1308
nitric oxide in	4453	in drug resistance	1305,1309
defects in apoptotic machinery of	4414	in HCV (hepatitis C virus)	1308
role of eNOS/iNOS in/regulation of	4459	Virtual high throughput screening	2099
Type I/type II apoptosis	111	3D pharmacophores for	2104
Type II diabetes	2564	1D/2D simple descriptors for	2100
Unbound drug	977	2D/3D fingerprints for	2101
in cancer therapy	982	fingerprint based selection methods for	2102

- molecular descriptors for2100,2104
selection methods used in 2105
virtual screening computing infrastructures
for 2106
- Vitiligo 3793
- Voltage-dependent anion channel (VDAC) 2249
as gatekeeper in mitochondria-mediated
apoptosis 2252
based biologic therapy 2264
channel activity of 2250
function in intracellular signaling 2249
in cell death 2249
in cell life 2249
in human disease 2264
isoforms of 2250
overexpression of 2263
regulation of associated activities of 2256
structure of 2250
- Voltage-gated potassium channels 2285
ancillary subunits on small-molecule
interactions with 2285
intracellular ancillary subunits of 2287
transmembrane ancillary subunits of 2289
with ion channel ancillary subunits 2286
- Voltage-gated sodium channels 3681
as targets in cancer therapy 3681
expression in patients 3687
in breast cancer 3687
in leukemia 3691
in lung cancers 3688
in prostate cancer 3682
TTX sensitivity of 3683
- Whey proteins/peptides 1637
anticancer activity of 1640
antimicrobial/bactericidal activity of 1641
as bioactive peptides 1641
immune function of 1640
in anxiety 1640
in depression 1640
in gastrointestinal health 1641
in HIV infection 1640
in oral health 1641
in oxidative stress 1640
in stress 1640
therapeutic use of 1639
- Whole embryo culture 1467
as part of validated embryotoxicity test 1481
as tool in developmental toxicology 1467
methodology of 1469
pharmacokinetic aspects in 1474
role in evaluation of embryonic
development 1473
standardization in 1471
test strategies with 1476
- Xenograft rejection 2383
mechanisms of 2383
pharmacological modulation of cytokines in 2383
- Xenotransplantation 2390
role of arachidonic acid metabolites in 2390
- Zalcitabine 1081
- Zidovudine 1079